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ABSTRACT OF DISSERTATION 
 
 
 
 
DISCOVERING A NOVEL ANTIFUNGAL TARGET IN DOWNSTREAM  
STEROL BIOSYNTHESIS USING A SQUALENE SYNTHASE FUNCTIONAL MOTIF 
 
The sterol biosynthetic pathway is essential for growth of all eukaryotic cells and the 
main target of antifungal agents.  The emergence of resistance to these antifungals in an already 
ill patient population indicates a need to develop drugs that have a broad spectrum of activity 
among pathogenic fungi and have minimal patient toxicity.  Squalene synthase is the first 
committed step in the sterol pathway and has been studied intensively for development of 
antifungal agents.  While the overall architecture of this enzyme is identical throughout 
eukaryotes, it was shown that plant and animal genes cannot complement a squalene synthase 
knockout mutation in yeast unless the carboxy-terminal domain is swapped for one of fungal 
origin. This implies that there is a component of the fungal carboxy-terminal domain that is 
responsible for the complementation phenotype and that is unique to the fungal kingdom of 
life.   
To determine the role of the carboxy-terminal domain of squalene synthase in the sterol 
pathway, we used the yeast Saccharomyces cerevisiae with a squalene synthase knockout 
mutation and expressed squalene synthases originating from fungi, plants, and animals.  In 
contrast to previous observations, all enzymes tested could partially complement the knockout 
mutation when the genes were weakly expressed.  When induced, non-fungal squalene 
synthases could not complement the knockout mutation and instead led to the accumulation of 
carboxysterol intermediates, suggesting an interaction between squalene synthase and the 
downstream sterol C4-decarboxylase. Overexpression of a sterol C4-decarboxylase from any 
kingdom of life both decreased the accumulation of carboxysterol intermediates and allowed 
non-fungal squalene synthases to complement the squalene synthase knockout mutation.   
Using chimeric squalene synthases from each kingdom of life, the motif in the C-
terminal domain responsible for preventing this toxicity was mapped to a kingdom-specific 26-
amino acid hinge motif adjacent to the catalytic domain. Furthermore, over-expression of the 
carboxy-terminal domain alone containing a hinge motif from fungi, not from animals or plants, 
led to growth inhibition of wild-type yeast. Since this hinge region is unique to and highly 
conserved within each kingdom of life, this data provides evidence for the development of an 
antifungal therapeutic as well as for tools to develop an understanding of triterpene catalytic 
activity and identify similar motifs in other biosynthetic pathways.  
 
 
 
 
KEYWORDS:  Squalene Synthase, Kingdom-specific Motif, Genetic Complementation 
                        Sterol C4-decarboxylase, Growth Inhibition 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            Kristin Brooke Linscott 
                                                            Student’s Signature 
                                                
                                                            6-20-2017 
                                                            Date 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
DISCOVERING A NOVEL ANTIFUNGAL TARGET IN DOWNSTREAM  
STEROL BIOSYNTHESIS USING A SQUALENE SYNTHASE FUNCTIONAL MOTIF 
 
 
 
By 
 
Kristin Brooke Linscott 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                 Dr. Joe Chappell 
                                                                                                           Director of Dissertation 
 
                                                                                                              Dr. Trevor Creamer 
                                                                                                      Director of Graduate Studies 
 
                                                                                                                      6-20-2017 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my father, for every pearl of wisdom 
and cup of coffee 
 
 
 
ACKNOWLEDGMENTS 
 
First and foremost, I would like to thank my mentor and chair of my committee, Dr. Joe 
Chappell, who created a supportive and engaging environment for my graduate training.  The 
work presented in this dissertation would not have been possible without his expertise, patience 
and generous guidance every step of the way.  I would also like to express my gratitude to each 
member of my dissertation committee, Dr. Todd Porter, Dr. David Watt, Dr. Craig Horbinski, and 
Dr. Matthew Gentry, as well as my outside examiner Dr. David Atwood.  Together they have 
provided invaluable advice and critical comments in regards to both my project and my career, 
encouraging me to strive for excellence.     
I thank Dr. Srebrenka Robic for sparking my interest in research during my 
undergraduate studies.   Thank you to the MD/PhD program, especially Dr. Susan Smyth and 
Therese Stearns for welcoming me into the program.  I thank all of the students of the MD/PhD 
program who have been good friends.  Thank you to the students ahead of me for all of the 
great advice, to the new students for sharing enthusiasm, and to all for constantly reminding me 
that I’m not alone on this journey.  I thank my graduate department, Molecular and Cellular 
Biochemistry, for teaching me not only about the natural world, but also how to best share my 
work with other scientists and the broader community. 
To all the members of the Chappell Laboratory, both past and present, you have all been 
a constant source of motivation and encouragement.  You have allowed me to stand on your 
shoulders and have walked with me in solidarity.  A special thanks to Dr. Tom Niehaus for 
blazing the trail on this project and performing some of the initial experiments.  Thank you to 
Xun Zhuang as well for her work creating the yeast lines that were so critical for this project. 
Thank you to Scott Kinison, who provided technical support throughout my graduate career and 
was always available to listen and design experiments. 
Finally, I would like to thank my family, who have loved, supported and encouraged me.  
I am grateful for the support of my mother and father, who taught me to explore the world 
around me and instilled in me a desire to care for others.  Thank you to my sister, who taught 
me to never stop questioning and learning.  Finally, I want to acknowledge my husband, Satrio 
Husodo, for his unwavering support throughout the years.      
iii 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................................. iii 
TABLE OF CONTENTS .............................................................................................................. iv 
LIST OF TABLES ............................................................................................................................ vi 
LIST OF FIGURES ......................................................................................................................... vii 
Chapter 1: Background and Introduction ................................................................................. 1 
The Emergence of Invasive Fungal Infections .............................................................................. 1 
The Development of Antifungal Therapeutics ............................................................................. 3 
Squalene Synthase Structure and Function ................................................................................. 4 
Scope of Dissertation ................................................................................................................... 9 
Chapter 2: Materials and Methods ........................................................................................ 10 
Yeast Lines and Growth Media .................................................................................................. 10 
Cloning Galactose-inducible Constructs .................................................................................... 11 
Yeast Transformation ................................................................................................................. 12 
Spot Plate and Growth Curve Analysis....................................................................................... 12 
Sterol Profile Analysis using GC-MS ........................................................................................... 14 
Protein Sequence Alignments and SQS Modelling .................................................................... 15 
Western Blot Analysis ................................................................................................................ 15 
Activity Assays ............................................................................................................................ 15 
Chemical Profiling for Squalene Accumulation .......................................................................... 16 
Chapter 3: Phenotypic Outcomes from Expression of Heterologous Squalene Synthases in 
Yeast ..................................................................................................................................... 17 
Introduction ............................................................................................................................... 17 
Results ........................................................................................................................................ 18 
Ergosterol prototrophy is restored by low level expression of a fungal or non-fungal SQS ... 18 
Low expression of a non-fungal SQS leads to low ergosterol levels and presqualene alcohol
 ............................................................................................................................................... 20 
Characterizing non-fungal SQS expression, activity, and localization ................................... 27 
Overexpression of a non-fungal SQS in ∆erg9 yeast prevents growth ................................... 30 
Sterol pathway analysis identifies a metabolic block after squalene biosynthesis ................ 39 
Discussion .................................................................................................................................. 42 
iv 
 
Chapter 4: Identification of a Metabolic Block Associated with the Heterologous Expression of 
Non-fungal Squalene Synthases in Yeast ................................................................................ 43 
Introduction ............................................................................................................................... 43 
Results ........................................................................................................................................ 49 
Yeast expressing a non-fungal SQS were rescued by blocking squalene flux ........................ 49 
Conversion of lanosterol to ergosterol is dependent on a fungal SQS C-terminal domain .... 52 
Manipulating carbon flux identifies a metabolic block in the C4 demethylation complex .... 55 
Sterol C4-decarboxylase expression enables a non-fungal SQS to complement a ∆erg9 
mutation in yeast ................................................................................................................... 58 
Expression of a non-fungal SQS leads to the production of carboxysterol intermediates ..... 65 
Discussion .................................................................................................................................. 72 
Chapter 5: Mapping a Kingdom-Specific Hinge Motif in the C-terminal Domain of Squalene 
Synthase ................................................................................................................................ 74 
Introduction ............................................................................................................................... 74 
Results ........................................................................................................................................ 75 
Mapping a functional motif in the C-terminal domain of SQS ............................................... 75 
Further narrowing down the critical residues in the hinge motif .......................................... 78 
Expression of the fungal SQS hinge motif inhibits growth of wild-type yeast ....................... 82 
Discussion .................................................................................................................................. 89 
Chapter 6: Additional Applications and Inferences: Investigating the Function of SQS Active 
Site Residues and Developing an Algorithm for Identifying Similar Motifs ............................. 95 
Introduction ............................................................................................................................... 95 
Results ........................................................................................................................................ 97 
Determining a complementation phenotype for SSL1-SSL3 constructs in ∆erg9 yeast ......... 97 
Library screening identifies mutations capable of converting the catalytic specificity of SSL3
 ............................................................................................................................................. 101 
Developing a naïve algorithm able to highlight the hinge motif of squalene synthase ...... 103 
Discussion ................................................................................................................................ 105 
Chapter 7: Concluding Remarks ........................................................................................... 110 
APPENDIX A: Abbreviations ................................................................................................. 112 
REFERENCES ........................................................................................................................ 113 
VITA .................................................................................................................................... 120 
 
v 
 
LIST OF TABLES 
 
Table 6.1:  Independent clones recovered from the SSL1-SSL3YCT mutant library on SC glucose 
and SC galactose solid media. ...................................................................................................... 102 
  
  
vi 
 
LIST OF FIGURES 
 
Figure 1.1:  Candida and Aspergillus are the most common fungi associated with invasive fungal 
infections in humans and there are few available treatment options. ........................................... 2 
Figure 1.2: Squalene synthase architecture and catalytic activity. .................................................. 6 
Figure 1.3: Alignment of SQS protein sequences representing each kingdom of life. .................... 7 
Figure 1.4: The sterol biosynthetic pathway in fungi and the sterol biosynthetic complex. ........... 8 
Figure 2.1: Protocol for yeast spot plate analysis.. ........................................................................ 13 
Figure 3.1: The C-terminal domain of a fungal SQS is necessary for accumulation of lanosterol 
and squalene epoxide .................................................................................................................... 19 
Figure 3.2: Complementation of a SQS knockout (∆erg9) yeast line with fungal and non-fungal 
SQS genes is dependent upon expression level ............................................................................. 21 
Figure 3.3: Low-level expression of a non-fungal SQS gene leads to low level accumulation of 
ergosterol and presqualene alcohol. ............................................................................................. 22 
Figure 3.4: The sterol profiles of SQS-deficient yeast expressing non-fungal SQS genes from each 
kingdom of life reveals the low level accumulation of ergosterol and presqualene alcohol ........ 24 
Figure 3.5: Sterol profile of wild-type yeast in SC glucose media. ................................................. 25 
Figure 3.6: Identification of presqualene alcohol in yeast by GC-MS analysis .............................. 26 
Figure 3.7: Quantification of SQS expression levels from each kingdom of life ............................ 28 
Figure 3.8: Comparison of SQS activity in vitro from various kingdoms of life. ............................ 29 
Figure 3.9: In vivo squalene accumulation following expression of SQS from various kingdoms of 
life .................................................................................................................................................. 31 
Figure 3.10: Growth and sterol profiles of ZX178-08 yeast cultures expressing wild-type yeast or 
human SQS genes grown in liquid cultures ................................................................................... 32 
Figure 3.11: Spot plate analysis of twenty colonies expressing an algal SQS with the ability to 
complement the ∆erg9 mutation in induction media with ergosterol. ........................................ 34 
Figure 3.12: Representative sterol profiles for yeast expressing an algal SQS and capable of 
growing on induction media .......................................................................................................... 35 
Figure 3.13: Inactive algal and yeast SQS proteins have impaired first half-reactions. ................ 37 
Figure 3.14: Combining an active algal SQS with an inactive yeast SQS recovers the 
complementation phenotype ........................................................................................................ 38 
Figure 3.15: Expression of an inactive yeast SQS partially inhibits growth of a ∆erg9 yeast line co-
expressing an active yeast SQS while allowing a non-fungal SQS to complement the knockout 
mutation. ....................................................................................................................................... 40 
Figure 3.16: The sterol profile of ZX178-08 yeast co-expressing algal and inactive yeast SQS ..... 41 
Figure 4.1: Toxic intermediates and side-products of the ergosterol biosynthetic pathway ........ 44 
Figure 4.2: The structures of intermediates in the downstream sterol biosynthetic pathway ..... 45 
Figure 4.3:  The structure, stereochemistry and numbering of lanosterol ................................... 46 
Figure 4.4: Three enzymatic steps in the C4 demethylation complex ........................................... 47 
Figure 4.5: Expression of non-fungal SQS, but not yeast SQS, is associated with the production of 
toxic downstream sterol metabolites ............................................................................................ 50 
vii 
 
Figure 4.6: Sterol profiles from yeast lines Δerg9,6 and Δerg9,3 expressing fungal or non-fungal 
SQS ................................................................................................................................................. 51 
Figure 4.7: Utilization of exogenous lanosterol in yeast is dependent on the presence of a fungal 
SQS ................................................................................................................................................. 54 
Figure 4.8: Growth of the yeast line ZX178-08 expressing an algal SQS improves with increasing 
levels of terbinafine. ...................................................................................................................... 56 
Figure 4.9: Removal of terbinafine from ZX178-08 yeast expressing a human SQS leads to 4,4-
dimethylzymosterol accumulation ................................................................................................ 57 
Figure 4.10: Co-expression of a non-fungal SQS with squalene epoxidase from a model grass in 
ZXB leads to 4,4-dimethylzymosterol. ........................................................................................... 59 
Figure 4.11: Overexpression of sterol C4-decarboxylase allows Δerg9,1 yeast to grow in the 
presence of exogenous lanosterol ................................................................................................. 60 
Figure 4.12: Alignment of the deduced sterol C4-decarboxylase amino acid sequences for sterol 
C4-decarboxylase genes from each kingdom of life ...................................................................... 62 
Figure 4.13: Co-expression of sterol C4-decarboxylase genes from any kingdom of life with a SQS 
gene from any kingdom of life is sufficient to complement a ∆erg9 mutation in yeast regardless 
of strong (galactose) or leaky (glucose) gene expression conditions ............................................ 63 
Figure 4.14: Co-expression of a non-fungal SQS with the S. cerevisiae sterol C4-decarboxylase 
returns the sterol pathway to a wild-type profile ......................................................................... 64 
Figure 4.15: Overexpression of a non-fungal SQS gene leads to accumulation of carboxy-sterol 
intermediates ................................................................................................................................. 66 
Figure 4.16: Low level expression of a non-fungal SQS led to accumulation of carboxy-sterol 
intermediates ................................................................................................................................. 67 
Figure 4.17: Mass spectra of putative carboxysterol intermediates ............................................. 68 
Figure 4.18: Accumulation of three carboxysterol intermediates in wild-type yeast following 
totarol treatment ........................................................................................................................... 70 
Figure 4.19: Yeast expressing a non-fungal SQS have lower total carboxysterol levels when co-
expressing an inactive yeast SQS or a C4-decarboxylase .............................................................. 71 
Figure 5.1: Mapping the SQS motif responsible for the functional complementation phenotype
 ....................................................................................................................................................... 76 
Figure 5.2: Alignments of the C-terminal domains of SQS enzymes from diverse fungi and from 
multiple kingdoms of life ............................................................................................................... 77 
Figure 5.3: A homology model of S. cerevisiae SQS and the hinge motifs from each kingdom of 
life. ................................................................................................................................................. 79 
Figure 5.4: Expression of SQS with a non-fungal hinge motif leads to carboxysterol accumulation
 ....................................................................................................................................................... 80 
Figure 5.5: The SKIEQ amino acid sequence in the hinge motif is critical for the fungal SQS 
complementation phenotype. ....................................................................................................... 81 
Figure 5.6: Examination of specific residues in the fungal SQS hinge motif for their contribution 
to the complementation phenotype. ............................................................................................ 83 
Figure 5.7: Effects of fungal and non-fungal SQS carboxy-terminal (CT) domains on growth of 
wild-type BY4741 yeast. ................................................................................................................. 85 
viii 
 
Figure 5.8: Fungal SQS carboxy-terminal domain expression inhibits wild-type yeast in a dose 
dependent manner. ....................................................................................................................... 86 
Figure 5.9: The fungal hinge motif is responsible for growth inhibition when expressing a SQS 
carboxy-terminal domain in wild-type yeast ................................................................................. 87 
Figure 5.10: Profiling sterol accumulation following expression of a fungal C-terminal domain in 
wild-type yeast. .............................................................................................................................. 88 
Figure 5.11: Fungal SQS carboxy-terminal domain expression inhibits yeast without a functional 
sterol biosynthetic pathway. ......................................................................................................... 90 
Figure 5.12: A conceptual model for how the organization of the sterol pathway might be 
facilitated by a non-catalytic hinge motif of SQS ........................................................................... 91 
Figure 5.13: Comparison of the hinge motifs of squalene synthases across kingdoms of life ...... 92 
Figure 5.14: Alignment of hinge motifs from SQS enzymes in each kingdom of life including 
protozoans. .................................................................................................................................... 94 
Figure 6.1: The SSL1-mtSSL3YCT construct produces increased squalene in yeast which feeds 
into the sterol biosynthetic pathway ............................................................................................. 98 
Figure 6.2: Expression of algal SQS genes produced by library mutagenesis and identified by 
screening for the non-fungal SQS growth phenotype. ................................................................ 100 
Figure 6.3: The 17glu26 and 17glu29 mutants have a converted product specificity but produce 
different levels of squalene ......................................................................................................... 104 
Figure 6.4: The naïve algorithm for identifying kingdom-specific motifs identifies the hinge motif 
of SQS ........................................................................................................................................... 106 
Figure 6.5: Currently available algorithms do not clearly identify the SQS hinge motif ............. 107 
ix 
 
Chapter 1: Background and Introduction 
 
The Emergence of Invasive Fungal Infections 
 While invasive fungal infections were once rare in a clinical setting, their emergence is 
now an important cause of patient morbidity and mortality [1].  For many years, invasive fungal 
diseases (involving blood, deep tissues, and organs) were caused predominantly by endemic 
fungi.  These fungi, such as Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides 
immitis/posadasii, were found in a particular geographic area due to local adaptation and host 
specificity [2–5].  Infections began in the lungs following inhalation of spores and then quickly 
progressed to deep viscera even in healthy individuals [6].  While these endemic fungi continue 
to infect patients, the epidemiology associated with invasive fungal infections has altered over 
the past few decades and now predominantly identifies opportunistic fungi in the expanding 
population of at-risk hospitalized patients.  Despite a growing body of evidence and knowledge 
about these fungi, the diagnosis and management of invasive fungal infections remains a 
challenge.   
Opportunistic infections specifically infect immunocompromised individuals.  Of the 
more than 18 different genera of opportunistic fungi that infect humans today, Candida species 
such as C. albicans, C. glabrata, C. krusei and C. parapsilosis represent the most common 
causative agents, accounting for between 46% and 53% of all reported cases.  They are also the 
most often isolated fungi in cases where the patients have solid tumors.  Aspergillus species, 
such as A. fumigatus, make up the second most common cause of invasive fungal infections 
(18%-24.8%) and are the most often associated with organ transplantation, particularly after 
hematopoietic stem cell transplantation [1,7] (Fig. 1.1A).  Opportunistic infections also include 
the less common fungi that are the cause of cryptococcosis and zygomycosis.   
The association of fungal infections with healthcare is a common one since 
opportunistic infections are often caused by improved medical technologies which increase the 
survival of patients with conditions that render them susceptible to infection.  For instance, 
patients with cancer are often at an increased risk of infection during chemotherapy, and many 
develop a lifelong susceptibility to certain infections even after cancer treatment has ended.  
Improved intensive care units treat patients with high doses of powerful antimicrobial drugs,  
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Figure 1.1:  Candida and Aspergillus are the most common fungi associated with invasive 
fungal infections in humans and there are few available treatment options.  (A) Of the 7 most 
common genera of fungi that cause invasive infections in humans, Candida (56%) and 
Aspergillus (22%) are the most common.  (B) The number and rate of development for available 
classes of systemic antifungal agents introduced to the clinic from 1950-2000 are listed with 
polyenes (red), cell cycle inhibitors (purple), azoles (green), allylamines (yellow), and 
echinocandins (blue).  This figure is modified from Menzin et al. (2009) and Ostrosky-Zeichner et 
al. (2010).
2 
decreasing competition between fungi and other microbes, and organ transplants often 
necessitate long-term use of immunosuppressive agents.  In these patients, even a small 
primary infection may progress to fulminant, disseminated disease if not properly treated [8].   
It is not surprising then that the frequency of invasive fungal infections due to these 
opportunistic pathogens has increased.  Hospitalizations caused by fungal infections rose by 
approximately 5.7% per year throughout the 1980s and early 1990s.  For Aspergillus alone, the 
increase was at least eightfold over this period of time [9].  Studies have shown that the number 
of cases of sepsis caused by fungi increased by 207% in the twenty years leading up to the turn 
of the century [10].  While there are only a few recent epidemiological reports concerning the 
incidence of invasive fungal infections, a review of these reports has suggested that more 
people worldwide die from the ten most prevalent invasive fungal diseases than from 
tuberculosis or malaria [11].  In one of the most complete studies of nosocomial bloodstream 
infections, the Surveillance and Control of Pathogens of Epidemiological Importance study 
(SCOPE) revealed that almost 10% of all infections were caused by fungi, and C. albicans was the 
fourth leading cause of blood stream infections [12].   
Perhaps the most striking finding is that the mortality rate for invasive fungal infections 
has not dramatically improved.  A nationwide study in France in 2014 found that among the 
3,600 patients who developed invasive fungal diseases, 28% died of complications arising from 
the infection [1].  Of the estimated 400,000 cases of candidemia that occur annually, the 
mortality rate is reported to be 42%, while the estimated 200,000 cases per year of invasive 
aspergillosis have a mortality rate that is consistently reported to be greater than 50%, and as 
high as 75-80% even if the patients are properly diagnosed and treated [11].   
 
The Development of Antifungal Therapeutics 
 The steadily increasing incidence of fungal diseases and disappointingly high mortality 
rates argue for a change in the way that we treat these infections.  Currently, one of the most 
limiting factors in clinical care of invasive fungal infections is diagnosis, as many of the current 
antifungal agents do not treat a broad spectrum of fungi.  Even when the causative agent has 
been identified, there are relatively few families of antifungal agents that treat systemic 
infections (Fig. 1.1B).  Compared to other pathogens, fungi are evolutionarily close to humans, 
and this has a limiting effect on drug discovery and development.  For this reason, therapeutic 
3 
 
targets often involve key steps in cell wall and membrane development, especially on the fungal 
membrane sterol, ergosterol, and its biosynthesis.   
 Of the antifungal agents available to clinics, three major classes inhibit the ergosterol 
biosynthetic pathway: allylamines, azoles, and polyenes.  The allylamine, terbinafine, inhibits the 
enzyme squalene epoxidase (Erg1) by binding to the enzyme and triggering a conformational 
change that prevents the substrate from binding [13].  While these drugs are fungicidal in 
susceptible species including many filamentous fungi, they are not capable of inhibiting the 
growth of most pathogenic yeast [14,15].  Azoles, such as fluconazole, inhibit the enzyme 
lanosterol C14-demethylase.  Unlike allylamines, the azoles are fungistatic and so require a 
functional immune system to remove the growth inhibited fungi.  Moreover, resistance to 
azoles is currently rising due not only to its common use in clinics but also to its use as an 
antifungal for crop management [16].  The polyenes are a class of compounds that bind to 
ergosterol and disrupt membrane permeability.  These toxic agents may cause severe and 
sometimes lethal multiple organ failure [17].  One other class of antifungal agents that is 
commonly used to target invasive fungal infections in clinics is the echinocandins, which target 
the enzyme complex responsible for synthesizing beta-(1,3)-glucan in the cell wall [18].  Unlike 
other antifungal agents, echinocandins have fungicidal activity against Candida species, even in 
critically ill patients..  However, clinicians are now observing an increase in fungi that are 
resistant to both azoles and echinocandins [19].   
Over the past decade, research has turned its focus toward other biosynthetic pathways 
and cellular components as potential targets for fungal growth inhibition, including amino acid 
and sphingolipid biosynthesis [20].  These drugs, while active against many varieties of 
pathogenic yeast, are not as active against pathogenic filamentous fungi like Aspergillus, and 
many are limited by toxicity.  Results like these, while they point to promising lead structures, 
have not yielded compounds with the desired potency, spectrum of activity, or safety necessary 
for clinical use.  These circumstances led to the studies reported in this thesis in which we 
sought to identify other potential therapeutic targets in the fungal sterol biosynthetic pathway. 
  
Squalene Synthase Structure and Function 
 The enzyme squalene synthase (SQS) has garnered attention in the research community 
for its role as the first committed step in the sterol pathway – a gatekeeper determining how 
carbon flux is distributed between sterols and other essential isoprenoids (6).  Initial interest in 
4 
 
using this enzyme as a drug target focused on the fact that it is downstream from HMG-CoA 
reductase in the cholesterol biosynthetic pathway.  Therefore, inhibition of sterol biosynthesis 
at this step would avoid a decrease in ubiquinone thought to be responsible for the 
development of myopathy, while still providing a similar mechanism of action to statins [21,22].  
While several inhibitors of squalene synthase have undergone early development as potential 
lipid-altering drugs, they have been associated with potential hepatic toxicity and have not 
completed clinical trials [23].  The viability of these inhibitors for decreasing cholesterol 
biosynthesis in humans is still questionable, but the use of SQS inhibitors is now widely studied 
for the production of anti-fungal therapeutics.  This enzyme is also believed to be a promising 
target for inhibiting growth of the protozoan parasites Leishmania donovani and Trypanosoma 
cruzi [20,24,25], and for disrupting virulence factor biosynthesis in the bacteria Staphylococcus 
aureus [26].   
Development of squalene synthase inhibitors is limited by the fact that the active site, in 
fact the overall architecture of this enzyme, is highly conserved throughout the eukaryotic 
kingdoms of life.  SQS consists of two domains: the amino (N)-terminal catalytic domain and a 
carboxy (C)-terminal domain responsible for tethering the enzyme to the cytosolic face of the 
endoplasmic reticulum (ER) (Fig. 1.2A).  Within the catalytic domain, alignment of the amino 
acid sequences from each of these SQS proteins revealed highly conserved sequences (domains 
I-V) responsible for the catalytic reactions performed by this enzyme (Fig. 1.3) [27].  First, head-
to-head dimerization of two molecules of farnesyl diphosphate (FPP) forms the intermediate 
presqualene diphosphate (PSPP) that contains a cyclo-propane ring.  The ring is cleaved followed 
by  reductive rearrangement with the co-factor NADPH to form squalene [28] (Fig. 1.2B).   
Squalene then proceeds into the sterol pathway where it is further activated by squalene 
epoxidase, then cyclized and modified to form ergosterol in fungi (Fig. 1.4A), cholesterol in 
mammalian cells, and the three major sterols in plants; stigmasterol, sitosterol, and campesterol 
[29].  The C-terminal membrane spanning helix is critical for localizing SQS to the ER membrane, 
where it is part of a complex network of protein-protein interactions involving the rest of the 
steps in this pathway.  Mo and Bard used a membrane-based yeast two-hybrid system to 
characterize interactions between all of the sterol biosynthetic proteins in S. cerevisiae and 
suggested that disruptions in this “ergome” may delocalize or destabilize other proteins 
impacting the efficiency of the pathway (Fig. 1.4B).   
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Figure 1.2: Squalene synthase architecture and catalytic activity. (A) A homology model of 
yeast SQS. This enzyme is composed of both a helical amino- terminal catalytic domain and a 
carboxy-terminal domain which includes a membrane spanning helix responsible for tethering 
the enzyme to the cytosolic face of the ER membrane. (B) SQS performs a reductive 
dimerization, converting two molecules of farnesyl diphosphate (FPP) to squalene through a 
two-step mechanism within a single active site cavity.    
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Figure 1.3: Alignment of SQS protein sequences representing each kingdom of life.  SQS 
protein sequences from each kingdom of life were aligned using the T-coffee algorithm.  
Sequences include: S. cerevisiae (yeast), A. thaliana (plant), H. sapiens (human), and B. braunii 
race B (algal).  The active site domains I-V (black) and carboxy-terminal domain (red) are 
underlined.  
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Figure 1.4: The sterol biosynthetic pathway in fungi and the sterol biosynthetic complex. (A) 
SQS is the first step (red arrow) in the ergosterol biosynthetic pathway converting farnesyl 
diphosphate (FPP) to squalene, a 30-carbon isoprenoid oxidized by squalene monooxygenase 
(Erg1) and cyclized by lanosterol synthase (Erg7).  In S. cerevisiae, ten additional enzymes modify 
the position of methyl groups and double bonds to form ergosterol.  Dashed lines indicate 
multiple steps in the pathway.  (B) These enzymes are all believed to be interconnected in a 
protein complex.  Each circle represents an enzyme in the S. cerevisiae sterol biosynthetic 
pathway, with lines depicting interactions identified by yeast 2-hyrbid analysis.  SQS (Erg9) is 
colored red.  This figure is modified from Mo and Bard (2005).  
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Scope of Dissertation 
 Considering the high morbidity and mortality associated with emerging invasive fungal 
infections as well as the limited range of antifungal agents available in clinics, there is a need for 
antifungal agents with novel biochemical targets.  The sterol biosynthetic pathway is a familiar 
but important target for the treatment of these infections, and the role of SQS as the first step 
in this pathway makes it an attractive option for drug development.  As previously discussed, 
the C-terminal domain of SQS is responsible for tethering the enzyme to the endoplasmic 
reticulum, but this domain has another fungal-specific function.  If a SQS is composed of a fungal 
C-terminal domain, not plant or animal, then it is able to complement a SQS knockout mutation 
in S. cerevisiae regardless of the origin of the catalytic domain.  And so, a small molecule or 
peptidomimetic aimed at disrupting this function has the potential to be a safe and specific 
inhibitor of fungal growth in humans with broad spectrum efficacy among pathogenic fungi.   
 In order to gain a clearer understanding of the SQS C-terminal domain, this dissertation 
aimed to characterize this region of SQS in terms of yeast growth and determine how it may be 
used for antifungal development.  Chapter 3 describes the phenotype of yeast expressing SQS 
genes from each different kingdom of life (fungal, plant, and animal) at both un-induced and 
induced levels and identifies a “toxicity” effect caused by over-expression of a non-fungal SQS.  
Chapter 4 investigates the role of SQS in the downstream sterol pathway and its effect on the 
activity of the C4 demethylation complex.  Chapter 5 maps a kingdom-specific 26-amino acid 
hinge motif in the C-terminal domain of SQS responsible for the growth phenotypes described in 
the previous chapters and verifies its potential use for the development of a fungal growth 
inhibitor.  Finally, we use the tools and knowledge gained through this investigation in the 
concluding chapter (Chapter 6) to develop a screen capable of evaluating active site residues of 
triterpene synthases and produce a preliminary algorithm for identifying other proteins with 
similar kingdom-specific motifs.  
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Chapter 2: Materials and Methods 
 
Yeast Lines and Growth Media 
 The yeast line ZX178-08 was produced by Zhuang and Chappell [30] from the parental 
line BY4741 (MATa;his3∆1;leu2∆0;met15∆0;ura3∆0).  In short, cells were mutagenized by EMS 
and plated on media containing nystatin, squalestatin, and cholesterol to select for colonies with 
a dispensable sterol pathway.  The ZX178 yeast line was then selected from this cohort for its 
ability to grow only in the presence of exogenous ergosterol and accumulate high levels of 
farnesyl diphosphate (FPP).  A targeted knockout mutation of the SQS gene was then performed 
by replacing the ERG9 gene with the hygromycin resistance gene hphNT1 [31].  Yeast line ZX178-
08 was selected for its ability to grow on complete media with added ergosterol and 300 mg/L 
hygromycin B. 
Additional targeted knockout mutations for yeast lines ∆erg9,1 (ZXB) and ∆erg9,7 (ZXE) 
were performed by Zhuang and Chappell using ZX178-08 [30]  In the same manner, the double 
knockout yeast lines ∆erg9,6 and ∆erg9,3 were produced using ZX178-08 as the parental line. 
The ERG6 and ERG3 genes were amplified using Takara high fidelity Primestar taq polymerase 
from yeast BY4741 genomic DNA.  The PCR fragment was purified, A tailed and ligated into the 
pGEM Teasy vector (Promega).  This construct was then used as a template for a second PCR 
reaction to obtain PCR fragments composed of only the 5’ and 3’ ends of the genes of interest to 
be used for homologous recombination.  Two cloning sites were then inserted into the middle of 
these two sequences and the Padh-Kanmx4-Tcyc-LoxP antibiotic selection marker cassette was 
inserted between these restriction sites.   
Yeast were grown without selection on YPD complete media with 1% Bacto-yeast 
extract, 2% Bacto-peptone, and 2% glucose (pH 5.3) or on synthetic complete (SC) media with 
0.67% yeast nitrogen base without amino acids (-his, -leu, -ura, and -trp) (Difco), appropriate 
amino acids for selection (250 mg/L histidine, 1 g/L leucine, 300 mg/L uracil, 150 mg/L 
tryptophan), 0.6% succinic acid and either 2% glucose or 2% galactose (pH 5.5). YPDE and SCE 
media were supplemented with ergosterol for growth of ergosterol dependent lines.  Solid YPDE 
and SCE media contained 4 mL of sterol stock solution (10 mg/mL ergosterol dissolved in Triton 
X-100 and ethanol 1:1) per liter while liquid YPDE and SCE media contained 0.5 mL of ergosterol 
stock solution per liter.  Stock solutions of lanosterol or cholesterol were made in a manner 
identical to ergosterol.  All solid media was prepared with 2% Bacto-agar. 
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Cloning Galactose-inducible Constructs 
 SQS genes (ERG9) from the yeast S. cerevisiae (X59959), A. nidulans (XM_655888), and 
C. albicans (D89610.1), the plants A. thaliana (NM_119630) and N. benthamiana (U46000.1), 
and the algae B. braunii (AF205791.1) were obtained from plasmids provided by Niehaus et al. 
[32].  The H. sapiens ERG9 gene (FDFT1, NM_004462) was obtained through the Harvard 
Medical Center’s DNA Resource CORE and was deposited by the NIH Mammalian Gene 
Collection (HsCD00331324).  All SQS genes were cloned into the Pesc-ura vector (Agilent) using 
NotI and SpeI restriction sites.   
The genes encoding for enzymes in the C4 demethylation complex of S. cerevisiae, sterol 
C4-methyloxidase (ERG25, NM_001181189.3), sterol C4-decarboxylase (ERG26, 
NM_001180866.1), and the sterol C3-ketoreductase (ERG27, NM_001181987.1), were amplified 
from BY4741 genomic DNA isolated using the YeaStar Genomic DNA Kit (Zymo Research).  To 
identify an algal sterol C4-decarboxylase gene (ERG26, SDC), transcriptomic sequencing was 
performed by Niehaus et al using RNA pooled from B. braunii cultures ranging from 1-4 weeks 
after subculturing [33].  The DNA sequence data obtained by two transcriptomic profiling efforts 
was assembled with the CLC Genomics Workbench (CLC Bio).  Screening of this dataset with the 
S. cerevisiae Erg26 amino acid sequence revealed an ORF encoding a 354 amino acid protein 
with a predicted molecular weight of 38,270 daltons.  The sterol C4-decarboxylase genes from B. 
braunii, A. thaliana (3βHSD/D1, NM_179448.3), and H. sapiens (NSDHL, NP_057006.1)  were 
cloned from cDNA.  Trizol was used to isolate total RNA from the respective species according to 
the manufacturer’s recommendations, which was then followed by cDNA synthesis using 
SuperScript III Reverse Transcriptase (Thermo Fisher Scientific).  All sterol C4-decarboxylase 
genes were cloned into the Pesc-his vector (Agilent) using NotI and SpeI restriction sites. 
Chimeric SQS genes were produced using an assembly PCR strategy described by 
Niehaus et al [33].  For instance, the Algal SQS with a yeast C-terminal domain (BS SQS) was 
created by first amplifying the B. braunii SQS catalytic domain with a 3’ extension corresponding 
to the 5’ sequence of the S. cerevisiae SQS C-terminal domain, and the C-terminal domain of the 
S. cerevisiae SQS with a 5’ extension corresponding to the 3’ end of the algal catalytic domain.  
The two PCR amplification products were then purified and used in a subsequent PCR reaction 
with the flanking primers.  The gene composed of an algal SQS with a yeast hinge motif (BSB 
SQS) was then created in a similar manner using the previous construct as a template. 
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 SQS C-terminal domains used to inhibit yeast growth were amplified from the 
corresponding full-length SQS genes and ligated into the Pesc-ura vector using the pGAL10 
promoter for 1x expression.  The C-terminal domains were then amplified again and inserted in 
the reverse orientation relative to the pGAL10 construct, but under the control of the pGAL1 
promoter for 2x expression.  Chimeric C-terminal domain expression vectors were amplified 
from the full length chimeric genes.  
 
Yeast Transformation 
 The recombinant vectors were transformed into each yeast line using a modified version 
of the lithium acetate method [6]. To produce competent cells, a 2 mL starter culture was 
inoculated with a single transformed yeast colony, grown for 2-3 days at 28°C shaking at 200 
rpm, and used to establish a 50 mL culture of YPDE media. The 50 mL culture was grown 
overnight in the same conditions to early exponential phase. The cells were briefly centrifuged 
and resuspended in 25 mL of a 1.2 M sorbitol wash buffer (1.2 M sorbitol in 0.1 M phosphate 
buffer at pH 7.5). This was followed by a second centrifugation and resuspension in 2.5 mL 
LioAC-PEG transformation buffer (0.1 M lithium acetate, 1 mg denatured sperm DNA, 34% 
PEGmW3350). Plasmid DNA (~1 μg) was combined with 200 μL of competent yeast and 
incubated at 30°C for 1 hr prior to a 10 minute 42°C heat shock. Transformed yeast were plated 
onto SCE glucose media lacking specific amino acids to select for auxotrophic markers. Yeast 
lines were confirmed to possess the various expression vectors by colony PCR and stored as 
glycerol stocks at -80⁰C.   
 
Spot Plate and Growth Curve Analysis 
 Yeast growth was analyzed using both spot plating and growth curves. For spot plate 
analysis, 2 mL starter cultures representing three independent colonies from each 
transformation were grown to stationary phase in SCE glucose (3 days) and rinsed with sterile 
water. The cultures were then diluted to an optical density of 1 at 600nm and 5x serial diluted 
three times using the cuvette station of a NanoDrop 2000c UV-Vis Spectrophotometer (Thermo 
Scientific) to produced four different optical densities: 1, 0.2, 0.04, and 0.008 at 600 nm. Four to 
five μL of each dilution were spotted on solid SC glucose or SC galactose media without specific 
amino acids for selection, with or without exogenous sterol. Photographs were taken after 5-7 
days of incubation at 28°C (Fig. 2.1).  
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Figure 2.1: Protocol for yeast spot plate analysis. Three 2 mL starter cultures representing 
independent colonies from each transformation were grown to stationary phase in SCE glucose 
and rinsed with sterile water. The cultures were then diluted to an optical density of 1 at 600nm 
and 5x serial diluted three times to produced four different optical densities: 1, 0.2, 0.04, and 
0.008.  4-5 μL of each dilution were spotted on various media types and photographs were 
taken after 5-7 days of incubation at 28°C.   
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For growth curve analysis, single colonies from a yeast transformation were used to 
inoculate starter cultures which were grown in 14 mL culture tubes at 28⁰C shaking at 200 rpm.  
Once the starter cultures reached stationary phase (3 days), they were used to inoculate 25 mL 
of liquid selection media containing glucose or galactose as the sole carbon source.  Cultures 
were grown at 28°C shaking at 200 rpm, and the optical densities were recorded at each time 
point. 
 
Sterol Profile Analysis using GC-MS 
For saponified sterol profiles, yeast were extracted based on a modified method by 
Quail and Kelly [34].  Cultures were started with single colonies grown in 2 mL of SCE glucose 
media to stationary phase, and these starter cultures were then used to inoculate 50 mL of SCE 
galactose induction media.  Once yeast reached roughly mid-exponential phase (OD600 = 5-8), a 
20 mL sample was collected at a normalized optical density equal to 5 at 600 nm.  Whole cells 
were resuspended in a saponification solution (2 mL of 60% KOH, 1 mL of 1% pyrogallol, and 2 
mL of methanol) in 24 mL glass vials with a screw cap, heated in an 80⁰C water bath for 2 hours 
and extracted three times with 5 mL heptane.  
To identify carboxysterols, yeast were grown and collected as described above. The 
cultures were then extracted according to the method of Bligh and Dyer [35].  Cells were 
collected by centrifugation for 10 min at 400xg, rinsed with sterile water, and resuspended in a 
24 mL glass vial with 1 mL of methanol and 0.5 mL of chloroform.  Four hundred µL of glass 
beads were added to the vial, which was vortexed at room temperature for 6 min at high speed.  
One-half mL of chloroform and one-half mL of ddH2O were added to the vial followed by 
vortexing for an additional 1.5 minutes.  The vial was centrifuged at 5,000xg for 4 minutes at 
room temperature to separate the two phases, and the lower chloroform layer was collected 
with a glass syringe and transferred to a clean vial.  Samples from both extraction methods were 
evaporated to dryness under nitrogen and derivatized using MSTFA + 1% TMCS (Thermo 
Scientific) in heptane. 
 GC-MS analysis was performed on an Agilent 7890A gas chromatograph with splitless 
injection coupled to an Agilent 5970C inert XL mass spectrometer with a triple-axis detector and 
an Agilent 19091S-433 capillary column (30 m x 250 µm).  The oven was programmed to hold at 
70⁰C for 2 minutes and then ramped to 270⁰C at a rate of 20⁰C/min.  Helium (10 psi) was used 
as the carrier gas, the electron ionization energy was 70 eV, and the inlet temperature 250⁰C.  
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Identification of sterols was achieved using purified squalene, lanosterol, zymosterol, and 
ergosterol standards, and the NIST (National Institute of Standards and Technology) reference 
database. 
 
Protein Sequence Alignments and SQS Modelling  
 The full-length SQS and C4-decarboxylase protein sequences, as well as the 26 amino 
acid hinge region of SQS were aligned using Vector NTI Software (Life Technologies). The full-
length yeast SQS protein structures from each kingdom of life were modelled with the help of 
the Zhan laboratory [36].  Homology models were created using the Protein Modeling module of 
Discovery Studio (version 2.5.5, Accelrys, Inc.) and the available crystal structure of H. sapiens 
SQS [37]. The missing C-terminal residues were modelled using the QUARK ab initio server. 
 
Western Blot Analysis 
 Yeast line ZXB (∆erg9,1) was transformed with Pesc-ura vectors containing amino-
terminal FLAG-tagged S. cerevisiae or B. braunii SQS genes.  Three independent transformants 
were selected and inoculated into 3 mL of SCE glucose media.  These starter cultures were 
grown at 28⁰C shaking at 200 rpm for three days.  A 25 mL culture of SCE glucose media was 
then inoculated 1:10 with 2.5 mL of the starter culture and incubated shaking at 28⁰C for 24 
hours.  Five mL of the culture were centrifuged for 10 minutes at 400xg, resuspended in 50 µL of 
ddH2O and combined with 10 µL of a 6x Laemmli buffer.  The sample was boiled in a water bath 
for 15 minutes and frozen at -80⁰C.  The remaining culture was centrifuged, the cell pellet 
washed, and the cells were resuspended in SCE galactose media.  After 3 days of induction, 5 mL 
of sample were removed from the culture and prepared in the same manner as the glucose 
sample.  Samples were then thawed on ice and 25 µL of each sample was loaded into an SDS 
PAGE gel along with 10 µL of SeeBlue Plus2 Pre-stained Protein Ladder (Thermo Fisher 
Scientific).  The protein was transferred to a nitrocellulose membrane and visualized using a 
monoclonal anti-FLAG antibody M2-alkaline phosphatase antibody and an anti-β actin loading 
control (Abcam). 
 
Activity Assays  
The various SQS genes were transformed in the yeast line ZXB (∆erg9,1) and liquid 
cultures were grown in SCE galactose induction media for 4 days. Microsomes were prepared 
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according to the methods of Pompon et al. (77). Enzyme assays contained microsomes (0.2 mg 
of membrane protein), 50 mM Tris-HCl, pH 7.4, 20 mM MgCl2, 5 mM NADPH and 30 μM FPP 
(S.A. ≈ 1250 DPM/pmol) in a total volume of 50 μL. The reaction mixture was incubated at 37°C 
for 1 hour followed by termination with 50 μL of 0.5 M EDTA. Hydrocarbons were extracted with 
200 μL hexane and used for TLC (silica gel 60 plates, hexane solvent). The squalene zone was 
scraped and quantified by liquid scintillation spectroscopy. Enzyme activity (pmoles/hr/μg total 
protein) is recorded as a percent of yeast S. cerevisiae SQS activity. 
 
Chemical Profiling for Squalene Accumulation 
 All chemical profiling was performed in the ZXB yeast line. Three biological replicates 
were selected to inoculate 3 mL starter cultures of SCE glucose media. The cultures were grown 
for 3 days at 28°C shaking at 220 rpm. Thirty µL of this culture was then used to inoculate 3 mL 
of SCE galactose media in a 14 mL culture tube, and the culture was grown at room temperature 
for 7 days shaking at 220 rpm. To extract hydrocarbons, 1 mL of culture was combined with 1 mL 
of acetone in a 4 mL glass screw cap vial and vortexed periodically for 20 minutes. One mL of 
hexane was then added and the vial was vortexed periodically for 30 more minutes. After 
separation of layers, 350 µL of the hexane phase was added to a 2 mL GC vial and evaporated 
under nitrogen.  Fifty µL of iso-octane was then used to reconstitute the sample and transfer it 
to a 250 µL GC vial insert.  One µL was analyzed via GC-MS. 
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Chapter 3: Phenotypic Outcomes from Expression of Heterologous 
Squalene Synthases in Yeast 
 
Introduction 
 A common method used to characterize a gene in any kingdom of life is functional 
complementation, adding DNA to a model organism that has a loss-of-function phenotype to 
see if the gene or genes of interest are able to restore the model organism to its wild-type 
phenotype.  The budding yeast, Saccharomyces cerevisiae, and the fission yeast, 
Schizosaccharomyces pombe, are often the model organisms used to test for complementation 
since genes of interest can be knocked out of the genome by homologous recombination [38].  
To design a screen capable of characterizing a human or plant gene in yeast, a ‘no growth’ 
phenotype is required that responds under clearly defined conditions, such as allowing putative 
complemented yeast to incubate under selective growth conditions.  To study genes for 
enzymes like SQS in the sterol biosynthetic pathway, researchers created yeast lines able to use 
sterols added to growth media under aerobic conditions.  This then allowed for the addition of 
knockout mutations [27,39,40], and growth was inhibited when the sterols were absent from 
the media unless the expressed ortholog complemented the knockout mutation.   
 The initial discovery and characterization of the genes encoding SQS (ERG9) occurred in 
the yeast S. cerevisiae, followed by S. pombe.  Together, these organisms paved the way for the 
preparation of ERG9 knockout yeast lines (∆erg9) to verify the identity of genes from both plants 
and animals [27,41,42].  Yet when the SQS genes identified in both humans and the model 
plants Arabidopsis thaliana and Nicotiana benthamiana were expressed in ∆erg9 yeast lines, 
they were unable to complement the mutation [43,44].  Conversely, expression of fungal SQS 
genes cloned from the dimorphic yeast, Yarrowia lipolytica, and more recently Ganoderma 
lucidum were able to complement the ∆erg9 mutation, a finding that suggested that there is a 
unique component of a fungal SQS that is required for SQS to function properly in yeast [45,46].   
 Robinson et al. first investigated whether or not there is a protein motif or domain 
required for the complementation phenotype [27].  These investigators reported that the 
human SQS protein displayed only modest levels of enzyme activity in yeast and that this activity 
was insufficient to complement the ∆erg9 mutation.  However, when a chimeric SQS gene was 
created producing a protein with the amino-terminal catalytic domain of the human SQS protein 
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linked to the membrane spanning C-terminal domain of the yeast SQS from S. cerevisiae, 
complementation was possible, and enzyme activity in yeast was restored.  These authors 
concluded that the human SQS might be misregulated when expressed in fungi, and the 
pathway was unable to produce adequate levels of the end product ergosterol. 
 Years later, Kribii et al. showed that SQS from the yeast S. pombe and the plant A. 
thaliana are both able to localize to the ER membrane in yeast and produce equivalent amounts 
of the product squalene [39].  This led to the conclusion that the lack of complementation was 
not the result of SQS mRNA expression levels or stability, but rather the result of an intrinsic 
feature of the protein unrelated to its catalytic activity or membrane localization.  Using 
chimeric enzymes in yeast microsomes and the radioactive substrate FPP, it was then 
demonstrated that yeast expressing a SQS protein with a non-fungal C-terminal domain were 
unable to convert the squalene into the next two intermediates in the sterol biosynthetic 
pathway, oxidosqualene and lanosterol (Fig. 3.1).  This led to the hypothesis that the C-terminal 
domain of a fungal SQS is necessary for the enzyme to integrate properly into the sterol 
biosynthetic complex.  In other words, without a component of the fungal C-terminal domain, 
SQS cannot effectively deliver squalene to the next step of the sterol pathway. 
 To define the non-catalytic functional role of a fungal SQS in sterol biosynthesis, we 
evaluated the ability of SQS proteins from three eukaryotic kingdoms of life to complement the 
∆erg9 mutation in the yeast S. cerevisiae.  Using a promoter system capable of both low and 
high level expression of each SQS gene, we provide evidence that the fungal SQS proteins have a 
structural feature unrelated to the enzyme’s catalytic capacity that is necessary for yeast 
growth.   
 
Results 
 
Ergosterol prototrophy is restored by low level expression of a fungal or non-fungal SQS 
 To verify that a non-fungal SQS cannot complement a strain of S. cerevisiae with a SQS 
genetic deficiency, we isolated plant, and animal SQS genes, as well as two recently identified 
algal SQS genes, and inserted these genes into an expression vector with the galactose-inducible 
promoter pGAL10.  When yeast are grown in media containing glucose, this promoter is greatly 
repressed, but not completely.  Once the yeast are suspended in media containing galactose as 
the sole carbon source, the promoter is induced and expression levels greatly increase [47].   
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Figure 3.1: The C-terminal domain of a fungal SQS is necessary for accumulation of lanosterol 
and oxidosqualene.  Microsomes were produced from yeast expressing the yeast S. cerevisiae 
SQS (red); plant A. thaliana SQS (green); or a chimeric SQS combining the N-terminal catalytic 
domain of the plant SQS with the C-terminal domain of the yeast SQS.  The microsomes were 
then incubated with the radioactive substrate for SQS, farnesyl diphosphate (FPP), and sterol 
extracts were analyzed by TLC.  FPP was either dephosphorylated to produce farnesol (FOH) or 
converted to squalene by SQS.  Squalene that enters the sterol pathway is converted to 
oxidosqualene and then lanosterol.  Homology models of yeast and plant SQS proteins are 
based on a published crystal structure of human SQS.  This figure is modified from Kribii et al. 
(1997).   
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Fungal genes were also isolated in order to compare expression of the non-fungal and fungal 
SQS enzymes.  We transformed these constructs, along with an empty expression vector, into 
the yeast line ZX178-08.  This line was produced using EMS mutagenesis to obtain a yeast line 
capable of aerobic sterol uptake, followed by complete replacement of the native SQS gene with 
a hygromycin selection marker using homologous recombination (∆erg9) [30].  Transformants 
were selected for their ability to grow on selective complete (SC) media containing glucose and 
exogenous ergosterol (SCE glucose), and three colonies from each transformation were selected 
to be biological replicates.  These colonies were grown in liquid SCE glucose media and 5-fold 
serial dilutions were spot plated on to media containing either glucose or galactose as a carbon 
source, with or without exogenous ergosterol (Fig. 3.2). 
 While yeast transformed with each of the SQS genes grew robustly on selection media 
containing glucose and exogenous ergosterol, the observed growth in glucose media without 
added ergosterol was unexpected.  Expression of a fungal SQS protein from S. cerevisiae, 
Candida albicans, or Aspergillus nidulans was able to complement fully the knockout mutation 
even at these low expression levels.  Since it has been reported that a mutated S. cerevisiae SQS 
with only 5% of the usual enzyme activity was still able to complement the knockout mutation in 
yeast [39], it is not surprising that very low expression of a highly active SQS in glucose 
conditions allowed the yeast to grow in the absence of added ergosterol.  Yeast cells expressing 
a non-fungal SQS gene from Arabidopsis thaliana, Nicotiana benthamiana, Panax ginseng, Homo 
sapiens, or Botryococcus braunii were able to grow under these non-inducing conditions, but the 
growth was greatly impaired.   
 
Low expression of a non-fungal SQS leads to low ergosterol levels and presqualene alcohol 
 Since growth of yeast expressing a non-fungal SQS was compromised in SC glucose, but 
was not impaired once exogenous ergosterol was provided, we investigated if a lower level of 
total ergosterol content was responsible for the growth inhibition.  Yeast transformed with each 
SQS gene were grown to mid-exponential phase in glucose media with and without added 
ergosterol.  The cells were then rinsed with sterile water, and 5α-cholestane was added as an 
internal standard.  Each sample was saponified, extracted with heptane and evaporated under 
nitrogen prior to derivatization and GC-MS profiling.  Figure 3.3 compares yeast expressing a 
representative fungal (S. cerevisiae) and plant (A. thaliana) SQS in each media type, and figure 
3.4 compares a non-fungal SQS from each kingdom of life in SC glucose media. 
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Figure 3.2: Complementation of a SQS knockout (∆erg9) yeast line with fungal and non-fungal 
SQS genes is dependent upon expression level.  The SQS genes from the fungi, S. cerevisiae, A. 
nidulans, and C. albicans (red); the plants, A. thaliana, N. benthamiana, and P. ginseng (green); a 
human (yellow); and an alga, B. braunii (blue) from either race B (BSS) or race L (LSS) were 
cloned under the control of a galactose-inducible promoter and expressed in ZX178-08 yeast 
(∆erg9). Three independent transformants for each construct (rows in each panel) were grown 
in SCE glucose to stationary phase, diluted to a normalized density and 5-fold serial dilutions 
were plated on media where the promoter is repressed (glucose) or induced (galactose) with or 
without ergosterol.  Images were taken after seven days of growth at 28°C.   
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Figure 3.3: Low-level expression of a non-fungal SQS gene leads to low level accumulation of 
ergosterol and presqualene alcohol.  Sterol profiles were obtained from SQS-deficient yeast 
expressing the yeast SQS from S. cerevisiae (red) or the plant SQS from A. thaliana (green) in 
glucose media with and without exogenous ergosterol.  Saponified and derivatized sterol 
extracts were analyzed by GC-MS.  Presqualene diphosphate (PSPP) is an intermediate in the 
conversion of FPP to squalene and is dephosphorylated in yeast to produce presqualene alcohol 
(PSOH).  5α-cholestane was added as an internal standard.  
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According to the cholestane internal standard, the extraction efficiency was consistently 
between 89 and 96% for these experiments.  SQS-deficient yeast harboring the wild-type SQS 
gene on a plasmid vector and grown under non-inductive conditions with and without 
exogenous ergosterol exhibited a sterol profile directly comparable to the sterol profile of the 
wild-type BY4741 yeast (compare figures 3.4 and 3.5), revealing that a fungal SQS fully recovers 
sterol pathway functionality.  Interestingly, the ergosterol levels were approximately 4 mg/g dry 
weight whether the S. cerevisiae SQS gene was located in its native genomic location or on a 
plasmid vector.  However, higher zymosterol and lower lanosterol accumulation were evident 
when the gene was expressed from an expression vector.  
In conditions where expression of plasmid localized genes would be minimal (SC 
glucose), yeast harboring the gene for a non-fungal SQS had an ergosterol content that was 
roughly 1/3rd to 1/5th lower than that of yeast harboring the wild-type S. cerevisiae SQS gene.  
While this showed that the sterol biosynthetic pathway was at least moderately functional, it 
was interesting to note that no sterol biosynthetic intermediates like lanosterol or zymosterol 
accumulated above the limits of detection.  Instead, a unique peak at approximately 12.2 
minutes was observed and identified as presqualene alcohol (PSOH).  This identification was 
based on expression of a previously characterized algal squalene synthase-like enzyme SSL-1 
which catalyzes the biosynthesis of presqualene diphosphate (PSPP) that desphosphorylates to 
presqualene alcohol (PSOH) in yeast due to endogenous phosphatases (Fig. 3.6) [33].  In the SQS 
catalytic cascade, PSPP is the product of the first half reaction which is not usually released from 
the enzyme unless the enzyme is NADPH-limited [48].  It is unclear why PSOH might accumulate 
when a non-fungal SQS is expressed at low levels, but may indicate that there are factors at play 
that influence the micro-environment surrounding the non-fungal SQS enzymes in the ER 
membrane.  These chemical patterns were unchanged when the yeast were grown in the 
presence of exogenous ergosterol, except that PSOH did not accumulate as much and the 
ergosterol content approximately doubled.   
These results provide two explanations for why yeast with a non-fungal SQS in SC 
glucose media might have a decreased growth rate.  First, Bell et al. reported that the 
accumulation of PSPP/PSOH can disrupt the normal growth rate of a ∆erg9 yeast line [49].  
Alternatively, the low level of ergosterol accumulation could be limiting for growth which can be 
restored by exogenous supplementation of ergosterol but not simple induced expression of the 
heterologous SQS gene.   
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Figure 3.4: The sterol profiles of SQS-deficient yeast expressing non-fungal SQS genes from 
each kingdom of life reveals the low level accumulation of ergosterol and presqualene 
alcohol. ZX178-08 yeast expressing SQS genes from each kingdom of life were grown in glucose 
media with or without exogenous ergosterol.  Saponified and derivatized sterol profiles were 
prepared and extracts were analyzed by GC-MS.   The SQS genes were from the alga, B. braunii 
race B (blue); human (yellow); plant, A. thaliana (green); and yeast, S. cerevisiae (red).  5α-
cholestane was used as an internal standard.  
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Figure 3.5: Sterol profile of wild-type yeast in SC glucose media. Wild-type haploid BY4741 
yeast were transformed with an empty vector and grown on SC glucose selection media without 
exogenous ergosterol.  Yeast were grown to mid-exponential phase; whole cells were 
saponified; and heptane extracts were derivatized prior to GC-MS analysis. Indicated sterols 
were identified using purified standards as well as the NIST database.   
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Figure 3.6: Identification of presqualene alcohol in yeast by GC-MS analysis.  SQS-deficient 
yeast were transformed with a fusion enzyme consisting of SSL-1 and SSL-3 from B. braunii, as 
well as an S. cerevisiae SQS membrane spanning domain. This chimeric enzyme produces the oil 
botryococcene, however the SSL-1 enzyme performs the first half-reaction of the enzyme SQS 
and releases the intermediate presqualene diphosphate (PSPP) which is converted to 
presqualene alcohol (PSOH) by endogenous phosphatases. Yeast were grown to stationary 
phase in selection media with added ergosterol, lysed using acetone, and the lysate was 
extracted with hexane. The extracts were derivatized and analyzed by GC-MS.  
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Characterizing non-fungal SQS expression, activity, and localization 
If low levels of ergosterol are the cause of slow growth, then it would follow that the 
non-fungal SQS enzymes are either producing less squalene for ergosterol biosynthesis, or the 
squalene produced cannot be properly converted to the end product in the pathway.  If non-
fungal SQS enzymes are producing less squalene than the native fungal counterpart, they could 
be poorly expressed, less active, or mislocalized within the ER membrane milieu in yeast.  To 
test this possibility, we expressed a SQS from each kingdom of life, as well as amino-terminal 
FLAG-tagged versions of each SQS in the ZXB yeast line.  This yeast line contains knockout 
mutations of SQS and the next enzyme in the sterol pathway, squalene epoxidase (∆erg9,1) [30].  
This allowed us to investigate not only the expression levels and activity of fungal and non-
fungal enzymes following induction but also the total amount of squalene produced in vivo over 
time.   
To test the expression levels of non-fungal SQS enzymes compared to a fungal SQS, we 
first grew three independent transformants containing the FLAG-tagged SQS genes in SCE 
glucose media to mid-exponential phase.  A portion of each culture was collected and stored to 
determine expression levels when the promoter was repressed.  The remainder of each culture 
was rinsed and resuspended in induction media with added ergosterol (SCE galactose).  After 60 
hours of induction, cells were collected, resuspended in sterile water with Laemmli buffer [50], 
and boiled prior to western blot analysis using anti-FLAG and anti-β actin antibodies (Fig. 3.7).  
There were no significant differences between expression levels of fungal vs non-fungal SQS 
proteins in yeast, and induction of the promoter with galactose increased the amount of SQS 
protein approximately nine-fold.   
Since SQS protein expression levels in this yeast line were not significantly different 
whether the protein was of fungal or of non-fungal origin, we next determined whether or not 
the protein activity varied.  Three independent transformants of yeast expressing each SQS were 
grown in SCE glucose media until the cultures reached stationary phase.  Sixty hours after 
galactose induction, microsomes were prepared, and enzyme activity assays were performed 
with [3H] FPP and NADPH.  Hydrocarbon reaction products were extracted with hexane and 
separated via thin layer chromatography.  The zone containing squalene was scraped and  
quantified by liquid scintillation spectroscopy (Fig. 3.8).  When induced, SQS enzyme activity in 
yeast containing a non-fungal SQS gene was on average 150% of that observed in yeast 
expressing a yeast SQS gene.    
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Figure 3.7: Quantification of SQS expression levels from each kingdom of life.  SQS-deficient 
yeast were transformed with N-terminal FLAG-tagged yeast (ScSQS), plant (AtSQS), human 
(HsSQS) and algal (BbSQS) SQS genes.  Three independent transformants for each construct 
were grown in SCE glucose (Glu) media to repress the pGAL10 promoter, and hence SQS gene 
expression.  Aliquots of the cultures collected in exponential phase of growth were switched to 
induction medium, SCE galactose (Gal), and all the cultures were continued to incubate for 60 
hours.  Samples were then collected and used for immunodetection of the SQS proteins via 
Western blotting (upper panel).  The lower panel represents quantification of the Western blots 
for all three independent samples.   
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Figure 3.8: Comparison of SQS activity in vitro from various kingdoms of life. The yeast line ZXB 
having both its native SQS gene and squalene epoxidase deleted (∆erg9,1) was transformed with 
plasmids harboring SQS genes of yeast (ScSQS, red), plant (AtSQS, green), human (HsSQS, 
yellow), or algal (BbSQS, blue) origins. Three independent transformants of each were grown in 
SCE galactose media to mid-exponential phase before microsomes were prepared for in vitro 
assays.  Results are presented in comparison (percent) to induced expression of the yeast SQS 
gene (red). 
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Squalene levels were also determined by growing each yeast line in SCE glucose or SCE 
galactose for seven days followed by cell lysis with acetone and hexane extraction (Fig. 3.9).  
While yeast expressing the SQS gene from S. cerevisiae produced far higher levels of squalene 
compared to yeast expressing the non-fungal SQS genes in both low and high expression 
conditions, yeast expressing the SQS gene from C. albicans produced less squalene than the 
algal SQS.  Since both the S. cerevisiae and C. albicans SQS proteins are able to complement the  
SQS genetic deficiency in yeast, the absolute level of squalene production does not appear to be 
the root cause limiting growth of the yeast transformed with the non-fungal SQS genes (Fig. 3.9).  
While the plant and human SQS genes were shown to be expressed at levels comparable to the 
fungal and algal SQS genes following induction (Fig. 3.7), squalene levels were approximately 
75% lower (Fig. 3.9).  One explanation for this difference may involve the stability of these 
enzymes in yeast over the course of the seven days that squalene was allowed to accumulate.       
These results suggest that all SQS enzymes tested are expressed and active in vivo.  
However, expression of a fungal SQS appears to favor carbon flux down the sterol biosynthetic 
pathway (as evident from the lanosterol, zymosterol and ergosterol accumulation patterns in 
figure 3.3) by a mechanism other than absolute SQS enzyme activity.   
 
Overexpression of a non-fungal SQS in ∆erg9 yeast prevents growth 
 As expected, expression of a fungal SQS readily complemented the ∆erg9 mutation 
when the promoter was induced by galactose, and the growth phenotype was largely 
unaffected by the presence or absence of added ergosterol (Fig. 3.2).  However, ∆erg9 yeast 
expressing a fungal SQS gene exhibit some loss of growth vigor (approximately 20%) as noted by 
a decrease in colony density as a function of serial dilutions.  Growth in liquid SCE galactose 
media revealed that yeast expressing the native yeast SQS had a longer lag phase than those 
harboring the empty vector control, yet the maximum growth rate and the final cell density 
were directly comparable (Fig. 3.10A).   
If a low level of ergosterol accumulation was responsible for the limited growth 
phenotype observed when the expression vector contained a non-fungal SQS gene and 
expression of the transgene was repressed by growth on glucose, then it would follow that 
increasing expression of SQS by switching the cultures to galactose (inducing) media should 
improve yeast growth.  However, yeast growth was almost completely inhibited once these non- 
fungal genes were induced for high level expression.  Interestingly, this growth inhibition 
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Figure 3.9: In vivo squalene accumulation following expression of SQS from various kingdoms 
of life. The yeast line ZXB having its native SQS and squalene epoxidase genes deleted (∆erg9,1) 
was transformed with plasmids harboring SQS genes of yeast (ScSQS or Candida albicans 
CaSQS), plant (AtSQS), human (HsSQS), or algal (BbSQS) origin. Three independent 
transformants for each were subsequently grown in SCE glucose or galactose for 7 days before 
quantifying the squalene levels using GC-MS.
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Figure 3.10: Growth and sterol profiles of ZX178-08 yeast cultures expressing wild-type yeast 
or human SQS genes grown in liquid cultures.  A) Yeast containing the empty vector or 
expressing the S. cerevisiae SQS (red) or human SQS (yellow) were grown in glucose (closed 
circles) or galactose (open circles) media with exogenous ergosterol.  The optical density of the 
culture was recorded every few hours over a period of 65 hours.  B) Yeast were grown in SCE 
galactose to mid-exponential phase, and cells were collected by centrifugation.  Non-
saponifiable lipids were extracted and derivatized heptane extracts profiled by GC-MS    
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occurred when expressing the SQS genes from P. ginseng and B. braunii race L, both of which 
have been shown to complement a SQS knockout mutation when induced in liquid media or 
expressed constitutively.  Consequently, there are mutations or growth conditions that do allow 
for some complementation [51,52].   
In these experiments, the only visible yet limited growth occurred on media containing 
exogenous ergosterol, suggesting that regulation of the sterol pathway or spontaneous 
mutations may allow the SQS genes to complement.  Twenty of the colonies able to grow in 
these conditions were inoculated into liquid media for low level SQS expression with exogenous 
ergosterol (SCE glucose) and then spotted again onto induction media with and without 
exogenous ergosterol (Fig. 3.11).  The non-saponifiable sterols for each of the colonies were also 
profiled (Fig. 3.12A).  All colonies retained the ability to grow on induction media with 
exogenous ergosterol (SCE galactose) although fifteen of the twenty colonies were unable to 
grow without exogenous ergosterol (SC galactose).  The sterol profiles for 14 of these colonies 
(represented by Colony 1) were identical to the profiles described previously (Fig. 3.3), while the 
sterol profile for colony 20 was highly similar to the profile of the SQS and lanosterol synthase 
double knockout yeast line (ZXE, ∆erg9,7) over-expressing an algal SQS (Fig. 3.12B).  Analysis of 
the gene for lanosterol synthase (ERG7) in this line identified the mutation F445G, and it has 
been suggested that a mutation from a phenylalanine to a hydrophobic residue at position 445 
of lanosterol synthase may disrupt electrostatic interactions in the active site cavity [53].  Four 
of the twenty colonies (represented by Colony 2) were able to grow in the absence of added 
ergosterol although growth was impaired.  The sterol profiles from each of these lines revealed 
an accumulation of squalene suggesting a change in squalene epoxidase activity.  Sequencing 
the gene for squalene epoxidase (ERG1) in each of these lines revealed the mutations L37P and 
G247D.  Each of these mutations have been shown to decrease enzymatic activity [54,55] 
These results were corroborated by the fact that the ZX178-08 yeast line (∆erg9) 
expressing an induced non-fungal SQS gene is sometimes able to grow in liquid induction media 
with added ergosterol (Fig. 3.10A); however, analysis of the sterol profiles from these cultures 
showed only squalene, oxidosqualene, dioxidosqualene, and the ergosterol from the media (Fig. 
3.10B).  When oxidosqualene accumulates, it is transformed by the enzyme squalene epoxidase 
to dioxidosqualene, so this profile was likely the result of a change in lanosterol synthase 
activity.  These results argue that over-expression of the heterologous SQS enzymes may lead to 
the build-up of a toxin, and that the toxin may be found in the  
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Figure 3.11: Spot plate analysis of twenty colonies expressing an algal SQS with the ability to 
complement the ∆erg9 mutation in induction media with ergosterol.  The yeast line ZX178-08 
(∆erg9) was transformed with an algal SQS gene and plated on media for gene induction (SCE 
galactose).  Twenty colonies were selected, grown in liquid SCE glucose to stationary phase, 
normalized to optical density and spotted onto induction media with and without added 
ergosterol.  .   
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Figure 3.12: Representative sterol profiles for yeast expressing an algal SQS and capable of 
growing on induction media.  A) Yeast from figure 3.11 were grown in liquid induction media 
with added ergosterol to mid-exponential phase.  Cells were collected by centrifugation, 
saponified and extracted with heptane.  Extracts were derivatized and analyzed by GC-MS.  B) 
Yeast line ZXE (∆erg9,7) was transformed with an algal SQS gene and grown in induction media 
prior to sterol profiling.   
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downstream sterol pathway since changes upstream appear to be responsible for the 
restoration of growth. 
SQS biological functions operate via distinct molecular mechanisms 
Our results suggest that fungal SQS may possess two functions in the sterol pathway: 
the first as an essential enzyme for sterol biosynthesis, and the second by providing the means 
to prevent toxin accumulation.  All the non-fungal SQS genes encode for catalytically active 
enzymes (Fig. 3.8), suggesting that preventing toxin accumulation may occur via a molecular 
mechanism that is not directly associated with catalytic activity.  To verify that these functions 
are independent, we generated point mutations in the yeast and algal SQS genes to disrupt 
enzyme activity.  An inactivating mutation in B. braunii race B SQS (A177N) was previously 
described disrupting the first of the SQS enzyme’s two half reactions [49].  By aligning the amino 
acid sequences of the B. braunii and S. cerevisiae SQS proteins, the corresponding mutation in S. 
cerevisiae SQS (A183N) was identified and introduced into the yeast gene.  In order to verify the 
effect of these mutations, the genes were co-expressed with the SSL-1 gene from B. braunii race 
B or an empty vector in the ZXB yeast line (∆erg9,1).  SSL-1 is able to catalyze only the first half 
reaction, converting two molecules of FPP to PSPP.  Cultures were incubated for seven days; the 
cells were lysed; and hexane extracts were examined for squalene by GC-MS (Fig. 3.13).  As 
expected, squalene was not detectable when yeast expressed only the inactive yeast or algal 
SQS enzymes; however, expressing these enzymes with SSL-1 led to detectable levels of 
squalene and two additional unknown triterpene peaks (1 and 2). 
These inactive SQS proteins were then expressed in combination with active algal and 
yeast SQS enzymes in the ∆erg9 yeast line.  Three independent transformants from each 
combination were spot plated on media to repress (glucose) and induce (galactose) the 
promoter, with and without added ergosterol (Fig. 3.14).  When expressed singularly, only the 
fully active, wild-type yeast SQS was able to fully complement the knockout mutation when the 
yeast were grown in all four conditions, as observed in figure 3.2.  The active algal SQS could not 
fully complement at low expression levels and induction led to complete growth inhibition. 
Neither the inactive yeast nor the algal SQS enzymes promoted growth of the yeast line, and like 
the yeast harboring the empty expression vector were only able to grow in the presence of 
exogenous ergosterol regardless of the induction conditions (glucose vs galactose media).   
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Figure 3.13: Inactive algal and yeast SQS proteins have impaired first half-reactions.  Yeast line 
ZXB (∆erg9,1) was co-transformed with the the A177N SQS mutant gene of B. braunii or the 
A183N SQS mutant gene from S. cerevisiae along with either an empty vector or the B. braunii 
SSL-1 gene encoding a PSPP synthase [33] and either Cultures were incubated at room 
temperature for seven days, lysed with acetone, and hexane extracts examined for squalene by 
GC-MS.  
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Figure 3.14: Combining an active algal SQS with an inactive yeast SQS recovers the 
complementation phenotype.  Yeast with a ∆erg9 mutation (ZX178-08) were transformed with 
combinations of active and inactive SQS genes from the yeast, S. cerevisiae, and alga, B. braunii 
race B. Independent transformants (rows) were diluted to an optical density of 1 at 600nm.  The 
cultures were serially dilutedfive-fold (columns) on to the designated media type.  Plates were 
grown for seven days at 28°C before imaging. 
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As predicted, the combination of an inactive yeast SQS that prevented toxin 
accumulation with an active algal SQS that produced squalene allowed the yeast to grow as if an 
active fungal SQS was expressed that was capable of carrying out both functions.  This was not 
the case when co-expressing the algal SQS with an inactive algal SQS.  Surprisingly, induction of 
both active and inactive S. cerevisiae SQS genes partially impaired yeast growth.  It is possible 
that very high level expression of a fungal SQS may disrupt interactions in the sterol biosynthetic 
complex and perhaps even other complexes in the ER membrane.  This would delocalize any 
binding partners and decrease the efficiency of ergosterol biosynthesis.  The ability of the 
A183N mutant fungal SQS gene to support complementation of the ∆erg9 yeast when co-
transformed with other non-fungal SQS genes was also extended to the human and plant SQS 
enzymes (Fig. 3.15). 
Sterol pathway analysis identifies a metabolic block after squalene biosynthesis 
We next analyzed the sterol biosynthetic pathway in yeast expressing fungal and non-
fungal SQS proteins, as well as the combination of an algal SQS with an inactive yeast SQS, 
following induction.  Yeast were transformed with constructs containing galactose-inducible SQS 
genes from S. cerevisiae and B. braunii race B, and colonies were used to inoculate flasks of 
liquid SCE glucose media.  Once cultures were grown to mid exponential phase (OD600 = 5), the 
cells were collected by centrifugation and rinsed with sterile water before resuspending them in 
SCE galactose.  After inducing for three days, non-saponifiable lipids were extracted with 
heptane and derivatized samples were analyzed by GC-MS (Fig. 3.16).   
Yeast expressing the active S. cerevisiae SQS produced ergosterol and many other 
identifiable sterol intermediates (Fig. 3.16).  In contrast, yeast expressing an algal SQS alone 
produced a low level of both squalene and ergosterol, and no other sterol intermediates 
accumulated above the level of detection.  These results mirrored those seen when expressing 
each SQS at low levels in glucose conditions (Fig. 3.3), and agreed with the previous findings of 
Kribii et al. that the squalene produced by a non-fungal SQS could not efficiently enter the sterol 
biosynthetic pathway.  It is possible that very low levels of a downstream sterol intermediate 
are sufficient to impair yeast growth and so this sterol is not identifiable by these methods of 
analysis.  As predicted, the sterol profile of yeast co-expressing the algal and inactive yeast SQS 
sufficient to impair yeast growth and so this sterol is not identifiable by these methods of 
analysis.  As predicted, the sterol profile of yeast co-expressing the algal and inactive yeast SQS 
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Figure 3.15: Expression of an inactive yeast SQS partially inhibits growth of a ∆erg9 yeast line 
co-expressing an active yeast SQS while allowing a non-fungal SQS to complement the 
knockout mutation.  Yeast with a ∆erg9 mutation were transformed with an inactive yeast SQS 
(ScSS A183N) and either a SQS gene from each kingdom of life or an empty vector with a 
galactose-inducible promoter. Three independent transformants (rows) were grown in SCE 
glucose liquid cultures for three days prior to normalizing culture density, then spotting five-fold 
serial dilutions (columns) onto the designated media types.  Plates were grown for seven days at 
28°C before imaging. 
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Figure 3.16: The sterol profile of ZX178-08 yeast co-expressing algal and inactive yeast SQS.  
Yeast line ZX178-08 was transformed with SQS genes from yeast, S. cerevisiae (red); alga, B. 
braunii (blue); or a combination of the algal SQS with an inactive A183N mutant yeast SQS 
(purple) under the control of a galactose-inducible promoter.  Yeast were grown in SCE glucose 
to mid-exponential phase and resuspended in SCE galactose induction media.  Cultures were 
normalized to optical density and nonsaponifiable sterols were derivatized for GC-MS analysis. 
4,4-DMZ = 4,4-dimethylzymosterol.
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genes mimicked that which was observed when expressing the active yeast SQS alone, 
demonstrating that the two functions of a fungal SQS can be expressed separately in yeast and 
fully rescue the sterol biosynthetic pathway. 
Discussion 
Previous studies have noted that while a non-fungal SQS cannot complement a ∆erg9 
mutation, constitutive expression in a double knockout yeast line (Δerg9,1) allowed significant 
levels of squalene to accumulate [30].  The results described here extend this observation in 
distinct ways.  Firstly, expression of a non-fungal SQS can partially restore sterol prototrophy 
and growth to a SQS deletion mutant if the heterologous SQS gene is expressed at a very low 
level.  While several groups have attempted complementation by expressing SQS genes from 
plants and humans using the strong galactose-inducible promoters, low or leaky expression of 
these genes under non-inductive conditions (glucose media) without added ergosterol was not 
tested previously [27,39,40].  This variability in growth does not appear to be caused by a 
difference in protein expression or activity as shown by both in vitro activity assays (Fig. 3.8) and 
by in vivo squalene accumulation (Fig. 3.9).   
Initially, we suggested that the impaired growth phenotype in non-inductive conditions 
could be the result of PSPP/PSOH accumulation or the result of low ergosterol production; 
however, PSOH was never identified when non-fungal protein expression was induced, 
suggesting that this intermediate only accumulates when SQS protein levels are low.  Similarly, 
the growth of yeast over-expressing a non-fungal SQS cannot be rescued by adding exogenous 
ergosterol.  We have demonstrated that the non-fungal protein itself is not toxic to yeast 
growth, as over-expression of an inactive algal SQS does not cause growth inhibition, and yeast 
lines with a decrease in lanosterol synthase activity are able to grow despite increased 
expression of an active human or algal SQS (Fig. 3.10 and 3.11).   
We suggest that there is a growth inhibitory intermediate or side-product in the sterol 
pathway that accumulates when a non-fungal SQS is expressed.  When low levels of squalene 
enter the pathway, this intermediate does not accumulate to levels that fully inhibit yeast 
growth and the ergosterol added to the media is able to dilute the effect of the aberrant sterol 
in the cell membrane.  Increasing expression of the non-fungal SQS, and therefore the level of 
squalene entering the sterol pathway, leads to such a high accumulation of the toxic 
intermediate that added ergosterol is no longer able to recover growth.  
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Chapter 4: Identification of a Metabolic Block Associated with the 
Heterologous Expression of Non-fungal Squalene Synthases in Yeast  
Introduction 
By inducing expression of heterologous SQS proteins in yeast with a knockout mutation 
in the resident SQS gene, we observed that expression of a non-fungal SQS leads to cessation of 
yeast growth even when a suitable source of exogenous sterol is provided.  Further analysis 
suggested that the growth inhibition phenotype could be suppressed by limiting the production 
of cyclized sterol intermediates.  Hence, we sought to identify whether a metabolic block in the 
sterol biosynthetic pathway caused by over-expression of heterologous SQS genes in yeast led 
to the accumulation of a toxic sterol(s).   
Squalene is converted to the end-product ergosterol in yeast through an additional 12 
enzymes that are responsible for 15 enzymatic steps (Fig. 4.1 and 4.2).  These steps can be 
divided into two distinct parts [29,56].  The first two steps after squalene biosynthesis form the 
first cyclized sterol intermediate.  Squalene is activated by squalene epoxidase (Erg1) that adds 
oxygen to the double bond between the second and third carbons (Fig. 4.3) [57–59].  
Oxidosqualene is then folded into the active site of oxidosqualene cyclase, also known as 
lanosterol synthase (Erg7), that catalyzes a complex carbocation mediated cyclization reaction 
yielding lanosterol.  Lanosterol is the first tetracyclic sterol intermediate and the precursor to 
the diverse array of sterols found in fungi, animals and plants [60,61].     
The second portion of the sterol pathway is a “tailoring” section that involves removal of 
methyl substituents, reducing and introducing double bonds, and addition of methyl and ethyl 
substituents to create the various sterols found in each kingdom of life.  In yeast, this section 
begins with lanosterol C14-demethylase (Erg11).  Removal of the methyl group at the C14 
position creates a double bond that is reduced by the sterol C14-reductase (Erg24) to yield 4,4-
dimethylzymosterol.  The next steps involve three enzymes that make up a C4 demethylation 
complex.  This complex, which has been identified in all kingdoms of life, involves three enzymes 
held together by the scaffold protein Erg28 [62–64].  As shown in figure 4.4, a sterol C4-
methyloxidase (SMO) converts one of the methyl groups in 4,4-dimethylzymosterol to a 
carboxylic acid intermediate.  A sterol C4-decarboxylase (SDC), also known as 3β-hydroxysteroid 
dehydrogenase/C4-decarboxylase or NSDHL in humans, affects the oxidation state at the C3  
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Figure 4.1: Toxic intermediates and side-products of the ergosterol biosynthetic pathway. 
Inhibition of various enzymes throughout the fungal sterol pathway are known to cause 
accumulation of intermediates and side-products (dark red) that inhibit yeast cell growth.  14-
Methylergosta-8,24(28)-dien-3,6-diol [65,66], carboxy- and keto-sterols [64,67,68] and ergosta-
7,22-dienol [69] have all been associated with toxicity effects in yeast.   
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Figure 4.2: The structures of intermediates in the downstream sterol biosynthetic pathway.  In 
fungi, lanosterol is converted to the end product ergosterol through thirteen enzymatic steps 
performed by ten enzymes.   
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Figure 4.3:  The structure, stereochemistry and numbering of lanosterol.  Sterols are named 
according to modifications of the backbone structure according to systematic rules agreed upon 
by the International Union of Pure and Applied Chemistry (IUPAC).  The substituent groups or 
other structural modifications are indicated by prefixes which include numbers indicative of the 
position in the carbon skeleton at which the modification occurs. 
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Figure 4.4: Three enzymatic steps in the C4 demethylation complex.  The C4 demethylation 
complex in fungi and human cells consists of three steps that convert 4,4-dimethylzymosterol 
into a carboxysterol and ketosterol, producing 4-methylzymosterol.  The three steps are then 
repeated to remove the second methyl group at the C4 position. 
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position resulting in decarboxylation at the C4 position to generate a C3-ketosterol 
intermediate.  The final step is performed by a sterol C3-ketoreductase (SKR) which produces 4-
methylzymosterol [29].  This complex of enzymes then repeats this sequence of reactions to 
remove the second C4-methyl group generating zymosterol.  The final five steps of the pathway 
finish remodeling zymosterol for the production of ergosterol.  These steps include a 
methyltransferase (Erg6), an isomerase (Erg2), two desaturases (Erg3 and Erg5) and a reductase 
(Erg4).   
Due to the importance of sterol metabolism for cell growth and its association with 
various disorders in humans, systematic mutagenesis and knock-out of genes in yeast have 
helped to map the biosynthetic pathway and uncovered suspected inhibitory intermediates and 
side-products.  For example, disruption of lanosterol synthase leads to the accumulation of 
dioxidosqualene which has a regulatory effect in human cells and slows the growth of S. 
cerevisiae.  Moving down the pathway, inhibition of the lanosterol C14-demethylase by either a 
knockout mutation or azole antifungal does not lead to accumulation of its substrate but rather 
to the development of a complex side-pathway involving sequentially the sterol C24-
methyltransferase, the C4 demethylation complex, and the sterol C5-desaturase.  This leads to 
the accumulation of the growth inhibitory side-product, 14-methylergosta-8,24(28)-dien-3,6-diol 
[65,66].  Inhibition of two steps in the C4 demethylation complex, the C4-decarboxylase and the 
C3-ketoreductase, lead to intermediates that may disrupt membrane architecture [64,67,68].  
The final five steps in the sterol pathway are not necessary for yeast viability; however, 
knockout mutations involving these enzymes were shown to produce side-products that slow 
yeast growth.  For instance, a mutant involving the sterol C5-desaturase accumulates ergosta-
7,22-dienol [70].   
In order to identify a region of the sterol biosynthetic pathway that may be responsible 
for the growth inhibition caused by expression of a non-fungal SQS in S. cerevisiae, various SQS 
genes under the control of a strong inducible promoter, the galactose-inducible gene expression 
system (pGAL), were analyzed for their impact on the growth of yeast cells in combination with 
other knockout mutations.  By combining this data with additional experiments using antifungal 
agents and expression of a heterologous squalene epoxidase, a gene that suppressed the 
growth inhibitory effect of non-fungal SQS expression in yeast was identified and led to the 
elucidation of the metabolic block and an intermediate that appears to be responsible for a toxic 
phenotype.  
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Results 
Yeast expressing a non-fungal SQS were rescued by blocking squalene flux 
If a toxin is produced in the pathway after squalene biosynthesis, then it follows that 
blocking squalene flux into the pathway with deletion mutations involving genes downstream of 
SQS should be able to recover the wild-type growth phenotype in the presence of exogenous 
ergosterol.  For this reason, deletion mutations involving the genes for squalene epoxidase 
(ERG1), lanosterol synthase (ERG7), sterol C24-methyltransferase (ERG6), and sterol C5-
desaturase (ERG3) were independently introduced into the SQS knockout yeast line ZX178-08.  
This created the double mutant lines ∆erg9,1 (ZXB), ∆erg9,7 (ZXE), ∆erg9,6, and ∆erg9,3, 
respectively.  Insertional inactivation of these genes was performed by introducing a G418 
resistance cassette surrounded by 5’ and 3’ segments of the target genes to promote 
homologous recombination.  Each yeast line was then transformed with an empty expression 
vector or galactose-inducible SQS gene.  Three independent transformants for each SQS gene 
were subsequently plated onto induction media containing ergosterol (Fig. 4.5).  The 
transformed yeast lines Δerg9,6 and Δerg9,3 were also grown in liquid glucose media with 
added ergosterol prior to inducing high level expression of introduced SQS genes.  The cells 
were the collected by centrifugation, saponified and the total extractable lipids derivatized for 
GC-MS analysis (Fig. 4.6).   
As expected, all of the yeast lines transformed with the empty expression vector grew 
well in induction conditions because exogenous ergosterol was included in the media, as did the 
yeast lines transformed with the S. cerevisiae SQS gene.  The ∆erg9,6 yeast line expressing a 
yeast SQS predictably accumulated the intermediate, zymosterol, the substrate for sterol C24-
methyltransferase which did not inhibit growth.  The growth rate of the ∆erg9,3 yeast line 
expressing yeast SQS was decreased compared to the other lines.  This may be due to the 
accumulation of ergosta-7,22-dienol.  Studies in the yeast C. albicans have shown that deletion 
of the sterol C5-desaturase (∆erg3) led to the accumulation of this side-product as well as a 
decreased growth rate [69].   
When squalene was blocked from entering the sterol biosynthetic pathway due to an 
additional knockout mutation involving squalene epoxidase (ERG1) or lanosterol synthase 
(ERG7), yeast expressing a non-fungal SQS were able to grow under induction conditions.  This 
suggested that the growth inhibition caused by expression of a non-fungal SQS was not caused  
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Figure 4.5: Expression of non-fungal SQS, but not yeast SQS, is associated with the production 
of toxic downstream sterol metabolites. Additional knockout mutations were created in the 
yeast line ZX178-08 involving the enzymes that appear after SQS in the sterol pathway, squalene 
epoxidase (Erg1) and lanosterol synthase (Erg7), as well as the sterol C24-methyltransferase 
(Erg6) and sterol C5-desaturase (Erg3) that appear at the end of the pathway. Yeast lines 
expressing the indicated SQS genes were grown on non-inducing media (SCE glucose) before 
three independent transformants for each construct were plated on inductive media with 
exogenous ergosterol (SCE galactose) and incubated for an additional seven days. 
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Figure 4.6: Sterol profiles from yeast lines Δerg9,6 and Δerg9,3 expressing fungal or non-fungal 
SQS.  Yeast lines ∆erg9,6, and ∆erg9,3 were transformed with either a fungal SQS from S. 
cerevisiae (ScSQS, red) or an algal SQS from B. braunii race B (BbSQS, blue).  Yeast were grown in 
non-inductive media to mid-exponential phase before collecting the cells by centrifugation and 
resuspending them in induction media.  The cultures were induced for an additional 30 hours 
prior to profiling total extractable lipids by GC-MS analysis.  4,4-DMZ = 4,4-Dimethylzymosterol 
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by accumulation of squalene or oxidosqualene forms but rather by a toxic intermediate or side-
product synthesized downstream of lanosterol synthase.  Conversely, growth was not recovered 
by deletion of the sterol C24-methyltransferase (Erg6) responsible for converting zymosterol 
into fecosterol or the sterol C5-desaturase (Erg3), that catalyzes the production of ergosta-
5,7,24(28)-trienol from episterol (Fig. 4.2).  Hence, a toxic intermediate or side-product appears 
to result from a change in metabolite flux in the center portion of the sterol pathway between 
lanosterol and zymosterol biosynthesis.   
The reason for creating a double knockout mutation involving the gene for the sterol C5-
desaturase (ERG3) was two-fold.  Not only did it verify that a toxin(s) was produced upstream of 
the C5-desaturase in the sterol biosynthetic pathway but also suggested that the metabolic 
block caused by expression of a fungal SQS was not at the level of the lanosterol C14-
demethylase (Erg11).  Hull et al. showed that C. albicans becomes resistant to azoles by 
decreasing the activity of the sterol C5-desaturase (Erg3) [66].  This led to an accumulation of 
14-methylfecosterol instead of a toxic diol, which the cells incorporate into membranes much 
like ergosterol (Fig. 4.1).  Since deletion of the ERG3 gene did not recover the wild-type growth 
phenotype following expression of a non-fungal SQS, growth inhibition in this instance does not 
appear to occur via the same mechanism induced by azole antifungals. 
 
Conversion of lanosterol to ergosterol is dependent on a fungal SQS C-terminal domain 
 While it may seem reasonable that accumulation of a toxic downstream sterol occurs 
because the non-fungal SQS enzymes generate too much squalene for the downstream sterol 
pathway compared to fungal enzymes, the results described in chapter 3 showed that 
complementation of the ∆erg9 yeast line did not correlate with SQS activity level (Fig. 3.8).  
However, the in vitro activity was determined in yeast microsomes, and in vivo squalene 
accumulation in a ∆erg9,1 yeast line.  Neither of these experiments allow for the possibility of 
feed-back regulation.  One hypothesis is that a downstream toxin/metabolite accumulates 
regardless of the origin of the SQS expressed.  This toxin/metabolite could then lead to feed-
back regulation of a fungal SQS, which may then contain motifs allowing for post-translational 
regulation of SQS enzyme activity.  This would lead to lower squalene levels and control of toxin 
accumulation.  The non-fungal SQS proteins would not be subject to such a post-translational 
regulation because they lack the protein motifs mediating this regulatory mechanism.  This, 
toxin accumulation would occur leading to growth inhibition.   
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If this were so, then simultaneous over-expression of both fungal and non-fungal SQS 
genes would be expected to exhibit the growth inhibition phenotype.  SQS activity would be far 
too great and the non-fungal SQS would not be regulated.  When both the yeast SQS gene from 
S. cerevisiae and the plant SQS gene from A. thaliana were co-expressed in each of the knockout 
yeast lines and three independent transformants of each were grown on induction media with 
added ergosterol, all yeast lines were able to grow equally as well as those lines only expressing 
a fungal SQS gene (Fig. 4.5). 
This unexpected result necessitated a second confirmation.  Hence, we sought to 
express non-fungal SQS genes in an otherwise wild-type yeast line.  We transformed BY4741 
(which harbors its own genomic SQS gene) with SQS genes from each different kingdom of life 
and streaked three independent transformants onto induction media with added ergosterol 
(Fig. 4.5).  Interestingly, this yeast line was able to grow regardless of whether a fungal or non-
fungal SQS gene was highly expressed.  These observations altogether suggested that it was not 
regulation of fungal SQS activity per se that prevented toxin accumulation in yeast.  Instead, 
there may be a structural feature(s) unique to the fungal SQS that is required to organize the 
sterol biosynthetic pathway and allow for the efficient flux of sterol intermediates to the end 
product ergosterol, thus preventing accumulation of a toxic intermediate or side-product.   
If a fungal SQS were necessary for efficient production of ergosterol from lanosterol 
then it would follow that the ∆erg9 yeast line would only be able to utilize exogenous lanosterol 
for growth when expressing a fungal SQS.  Growth of yeast with an empty vector or a non-fungal 
SQS should be inhibited since lanosterol would be expected to enter the sterol pathway and be 
converted into the toxic intermediate rather than ergosterol.  The ZXB yeast line (∆erg9,1) was 
used so that any squalene produced would not be able to enter the sterol pathway, and yeast 
growth would be dependent on exogenous lanosterol.  ZXB was therefore transformed with 
both fungal and non-fungal SQS genes, as well as a fungal mutant SQS gene (SQS A183N) that 
encoded for a catalytically impaired squalene synthase enzyme.  Three independent 
transformants for each construct were then spotted onto glucose or galactose media containing 
either exogenous ergosterol or lanosterol (Fig. 4.7).  Because the ZXB line harbors a deletion of 
the squalene epoxidase gene (∆erg1), squalene produced via either the fungal or non-fungal SQS 
would not be able to enter the sterol biosynthetic pathway and hence, all transformed yeast 
would be expected to be dependent upon exogenous ergosterol to grow.  As shown in figure 4.7 
53 
Figure 4.7: Utilization of exogenous lanosterol in yeast is dependent on the presence of a 
fungal SQS. Yeast line ZXB (∆erg9,1) was transformed with either an empty vector or a SQS gene 
from a yeast, S. cerevisiae (red); plant, A. thaliana (green); human, H. sapiens (yellow); or alga, 
B. braunii (blue).  An expression vector containing an inactive yeast SQS gene with an A183N 
point mutation was also transformed.  Three independent transformants for each construct 
(rows in each panel) were grown in SCE glucose to stationary phase, diluted to a normalized 
density and 5-fold serial dilutions were plated on media where the promoter is repressed 
(glucose) or induced (galactose) with either ergosterol or lanosterol.        
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this was the case.  When lanosterol was added as the source of exogenous sterol, only yeast 
expressing an active or an inactive S. cerevisiae SQS were able to grow.  Growth of yeast 
expressing either the empty vector or a non-fungal SQS was inhibited. 
Manipulating carbon flux identifies a metabolic block in the C4 demethylation complex 
In an effort to accumulate enough of a putative toxic intermediate prior to cell growth 
arrest or feedback inhibition, we used the antifungal agent terbinafine to inhibit the enzyme 
squalene epoxidase (Erg1).  To optimize the concentration of terbinafine used in each culture, 
Δerg9 yeast expressing the algal SQS from B. braunii race B were grown in induction media with 
exogenous ergosterol (SCE galactose) and 0-64 µg/mL of terbinafine.  The double knockout yeast 
line ZXB (∆erg9,1) expressing algal SQS was grown simultaneously without terbinafine as an 
example of yeast growth when squalene epoxidase activity was absent.  Growth was quantified 
by measuring the optical density at 600 nm over time (Fig. 4.8).  While the ∆erg9 yeast cultures 
without terbinafine did not grow significantly over the course of 45 hours, increasing amounts of 
terbinafine improved the growth rate.  Cultures grown with 64 µg/mL of terbinafine grew at a 
rate similar to the ∆erg9,1 yeast line, indicating that additional terbinafine would not be able to 
further over-come the growth inhibition.   
Yeast expressing each non-fungal SQS were then grown in SCE galactose media 
containing 64 µg/mL terbinafine to mid-exponential phase.  To remove the terbinafine 
treatment from the cultures, the cells were collected by centrifugation and resuspended in 
water six times.  The cells were then resuspended in galactose induction media and incubated 
for various lengths of time before being profiled for their total lipid contents by GC-MS (Fig. 4.9).  
Prior to rinsing the cells, chromatograms showed that terbinafine was present and squalene 
greatly accumulated.  After washing out the terbinafine, squalene was able to enter the sterol 
pathway, and cyclized sterol intermediates began to accumulate.  For yeast expressing a yeast 
SQS from S. cerevisiae, the sterol profile mirrored that of wild-type yeast BY4741 within three 
hours.  In contrast, only about half of the terbinafine could be removed from the cells expressing 
a non-fungal SQS suggesting some change in cell permeability.  Most striking, only lanosterol 
and 4,4-dimethylzymosterol began to accumulate by the twelve hour time-point, and no 4-
methylzymosterol or zymosterol were detectable. 
For the same reason, a non-fungal squalene epoxidase from the model grass 
Brachypodium distachyon (BdSQE1) was also expressed in the yeast lines.  Preliminary results 
had shown that this epoxidase was not able to utilize squalene as efficiently in yeast as the  
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Figure 4.8: Growth of the yeast line ZX178-08 expressing an algal SQS improves with 
increasing levels of terbinafine.  Yeast line ZX178-08 (∆erg9) was transformed with an algal SQS 
gene under the control of the galactose-inducible promoter.  The  ZXB yeast line (∆erg9,1) was 
transformed with with the empty expression vector.  The resulting transformants were grown in 
SCE glucose media to stationary phase, and these starting cultures were used to inoculate 
cultures containing induction media (SCE galactose with varying concentrations of terbinafine. 
Growth was analyzed at the indicated time points by measurement of the cultures optical 
density (OD600).  
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Figure 4.9: Removal of terbinafine from ZX178-08 yeast expressing a human SQS leads to 4,4-
dimethylzymosterol accumulation.  Yeast line ZX178-08 (∆erg9) was transformed with an S. 
cerevisiae or H. sapiens SQS gene under the control of a galactose-inducible promoter.  Cultures 
were grown in the presence of 64 mg/mL terbinafine in induction media containing ergosterol 
(SCE galactose) until mid-exponential phase of growth before cells were then washed with 
sterile water, resuspended in induction media (SCE galactose) and incubation continued.  Cells 
were collected every three hours, saponified and derivatized heptane extracts were analyzed 
using GC-MS. 4-MZ = 4-methylzymosterol; 4,4-DMZ = 4,4-dimethylzymosterol. 
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S. cerevisiae squalene epoxidase.  We reasoned that expression of this enzyme in tandem with 
the various SQS genes in yeast line ∆erg9,1 would temper the accumulation of the toxin, 
possibly allowing for a greater chance to visualize toxin accumulation by GC-MS.  The ∆erg9,1 
yeast line transformed with BdSQE1 as well as a SQS gene from each kingdom of life were grown 
for three days in induction media before analyzing sterol profiles by GC- MS (Fig. 4.10).  Yeast 
expressing the S. cerevisiae SQS grew to stationary phase and accumulated each of the expected 
sterol intermediates, expression of non-fungal SQS genes again led to the accumulation of 
lanosterol and 4,4-dimethylzymosterol.  While there is no precedence for 4,4-
dimethylzymosterol inhibiting yeast growth [71,72], both of these intermediates are methylated 
at the C4 position suggesting that the cells expressing a non-fungal SQS gene were unable to 
demethylate the C4 methylated intermediates.  
 
Sterol C4-decarboxylase expression enables a non-fungal SQS to complement a ∆erg9 mutation 
in yeast 
 Although an unusual or toxic sterol intermediate was not identified in the foregoing 
experiments using terbinafine or a poorly active squalene epoxidase , they hinted at a limitation 
of the C4 demethylation complex in those lines not expressing a fungal SQS gene.  To evaluate 
this possibility, enzymes in the C4 demethylation complex were over-expressed in an attempt to 
overcome this putative metabolic block.  Each of the three S. cerevisiae genes involved in this 
complex were PCR amplified and inserted behind a galactose-inducible promoter, transformed 
into the ZXB yeast line (∆erg9,1) and three independent transformants plated onto induction 
media containing either ergosterol or lanosterol (Fig. 4.11).  Expression of genes corresponding 
to the first and third steps of this complex, the methyloxidase (ERG25) and ketoreductase 
(ERG27), did not allow the yeast line to grow in the presence of lanosterol.  However, yeast 
expressing the gene for the S. cerevisiae sterol C4-decarboxylase (ERG26) were able to grow and 
mimicked the growth phenotype observed when expressing a fungal SQS.   
 Since increased levels of the yeast sterol C4-decarboxylase rescued growth of the SQS 
knockout yeast line and prior work demonstrated the importance of the C-terminal domain of 
fungal SQS in the complementation phenotype, it was reasonable to examine whether or not 
the C-terminal domain of the fungal SQS could mediate the efficiency of the sterol C4 
demethylation steps..  If so, a hypothesis would be that induced expression of the yeast ERG26 
gene would be able to rescue growth of yeast expressing a non-fungal SQS.  Furthermore, if the  
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Figure 4.10: Co-expression of a non-fungal SQS with squalene epoxidase from a model grass in 
ZXB leads to 4,4-dimethylzymosterol.  Yeast line ZXB (∆erg9,1) was transformed with a SQS 
gene from a yeast, S. cerevisiae (red); plant, A. thaliana (green); human, H. sapiens (yellow); or 
alga, B. braunii (blue) under the control of a galactose-inducible promoter as well as a galactose-
inducible squalene epoxidase gene (ERG1) from the model grass B. distachyon.  Yeast cultures 
were grown first in SCE glucose media and induced by centrifuging the cultures and 
resuspending the cell pellets in SCE galactose media.   Saponified and derivatized sterol extracts 
were analyzed by GC-MS.  4,4-DMZ = 4,4-dimethylzymosterol. 
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Figure 4.11: Overexpression of sterol C4-decarboxylase allows Δerg9,1 yeast to grow in the 
presence of exogenous lanosterol. Yeast line ZXB (∆erg9,1) was transformed with genes from 
the yeast S. cerevisiae responsible for C4 demethylation, sterol C4-methyloxidase (ERG25, SMO), 
sterol C4-decarboxylase (ERG26, SDC), and sterol C3-ketoreductase (ERG27, SKR), under the 
control of a galactose-inducible promoter.  Three independent transformants representing each 
construct were grown in non-inducing media (SCE glucose), density normalized, five-fold serial 
diluted, and plated on glucose and galactose media containing either ergosterol or lanosterol. 
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yeast SQS is involved in a fungal-specific protein-protein interaction with a yeast C4-
decarboxylase, then it would follow that the plant C4-decarboxylase would specifically detoxify 
yeast expressing the plant SQS, or the human C4-decarboxylase would recover growth of yeast 
expressing the human SQS.  Plant, human, and algal genes for sterol C4-decarboxylase were PCR 
amplified, verified by DNA sequencing (Fig. 4.12) and subsequently co-transformed into the 
ZX178-08 (∆erg9) yeast line with expression vectors containing genes for SQS and sterol C4-
decarboxylase expression.  Three independent transformants from each combination were first 
grown to stationary phase in SCE glucose, then serial dilutions were spotted on media for either 
low or high level expression with and without exogenous ergosterol.  Contrary to our 
expectations, expression of any sterol C4-decarboxylase gene was able to restore the growth 
phenotype regardless of the co-expressed SQS gene (Fig. 4.13).   
Yeast co-expressing a fungal C4-decarboxylase and a SQS from any kingdom of life were 
also examined for their sterol profile.  Cultures were first initiated in SCE glucose, then switched 
to induction media (SCE galactose) and induced for an additional three days.  Non-saponifiable 
lipids were extracted and derivatized samples examined by GC-MS (Fig. 4.14).  Most striking was 
that the total sterol profiles for all of the different lines were nearly identical to one another and 
to the capitulation of the fungal SQS gene with the fungal C4-decarboxylase gene, regardless of 
the SQS gene they harbored and as long as they co-expressed the fungal C4-decarboxylase gene. 
 When expressing a yeast C4-decarboxylase from S. cerevisiae, the growth phenotypes 
for fungal and non-fungal SQS expression on glucose containing media were unchanged.  Those 
expressing the yeast SQS grew well while yeast expressing a non-fungal SQS displayed an 
impaired growth phenotype.  Once induced, however, the yeast C4-decarboxylase was able to 
rescue growth of yeast over-expressing a non-fungal SQS.  Just like induced co-expression of 
both the active and inactive forms of a fungal SQS in figure 3.14, high level co-expression of the 
yeast SQS along with the yeast C4-decarboxylase impaired growth of the ∆erg9 yeast line.  
Interestingly, sterol profiles confirmed that the sterol biosynthetic potential was functionally 
equivalent whether the sterol C4-decarboxylase was over-expressed with a fungal or non-fungal 
SQS.  Co-expression of a plant, human, or algal C4-decarboxylase was able to restore the wild-
type growth phenotype in all media types no matter the origin of the SQS.  Altogether, these 
results point to some interruption of the sterol demethylation complex as a result of 
heterologous expression of SQS genes in the ERG9 mutant yeast and that either over-  
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Figure 4.12: Alignment of the deduced sterol C4-decarboxylase amino acid sequences for 
sterol C4-decarboxylase genes from each kingdom of life.  Protein sequences for sterol C4-
decarboxylase (Erg26, SDC) from S. cerevisiae (ScSDC), A. thaliana (AtSDC), H. sapiens (HsSDC), 
and B. braunii race B (BbSDC) were deduced from conceptual translations of the respective PCR 
amplified genes and aligned using the T-coffee algorithm. 
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Figure 4.13: Co-expression of sterol C4-decarboxylase genes from any kingdom of life with a 
SQS gene from any kingdom of life is sufficient to complement a ∆erg9 mutation in yeast 
regardless of strong (galactose) or leaky (glucose) gene expression conditions.  The sterol C4-
decarboxylases genes (ERG26, SDC) from each kingdom of life were transformed with an empty 
expression vector or a SQS gene from a yeast, S. cerevisiae (red); plant, A. thaliana (green); 
human, H. sapiens (yellow); or alga, B. braunii (blue) . Independent transformants (rows on each 
plate) were five-fold serial diluted three times (columns) and spotted onto each media type. 
Plates were grown for 7 days at 28°C before imaging. 
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Figure 4.14: Co-expression of a non-fungal SQS with the S. cerevisiae sterol C4-decarboxylase 
returns the sterol pathway to a wild-type profile. Yeast line ZX178-08 (∆erg9) was transformed 
with galactose-inducible SQS genes from S. cerevisiae (red), A. thaliana (green), H. sapiens 
(yellow), and B. braunii (blue) in combination with the S. cerevisiae sterol C4-decarboxylase 
gene. Cultures were grown in non-inducing media (SCE glucose), centrifuged and the cell pelletts 
resuspended in induction media (SCE galactose).  After three days of further incubation, culture 
densities were normalized and cells were saponified followed by heptane extraction.  The non-
saponifiable sterols were derivatized and analyzed by GC-MS. 
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expression of a fungal or non-fungal C4-decarboxylase suffices to complement this deficiency. 
This complementation may arise because the heterologous C4-decarboxylases are more active 
in yeast than the native yeast C4-decarboxylase or because they are not subject to the same 
regulation as the native yeast C4-decarboxylase.   
Expression of a non-fungal SQS leads to the production of carboxysterol intermediates 
The disruption of sterol C4-decarboxylase activity using either a full knockout mutation 
of the ERG26 gene [67] or a temperature-sensitive mutation [73] was shown to disrupt cell 
growth and led to the accumulation of toxic carboxysterol intermediates [67].  To determine if 
such intermediates could be accumulating under some of the conditions described here, it was 
necessary to adjust the sterol extraction procedure.  We grew the ∆erg9 yeast line transformed 
with SQS genes from each kingdom of life in SCE glucose to mid-exponential phase and induced 
expression with SCE galactose for three days.  Cultures were normalized via optical density 
before performing a Bligh and Dyer total lipid extraction using chloroform and methanol in the 
presence of acid-washed glass beads.  Figure 4.15 shows the resulting chromatograms from GC-
MS analysis of derivatized lipids at m/z = 468 which highlights both the changes in ergosterol 
levels and the presence or absence of carboxysterol intermediates. 
Yeast transformed with an empty vector accumulated low levels of ergosterol from the 
growth media, and there was no evidence of any additional sterol intermediates.  Following 
expression of a yeast SQS from S. cerevisiae or C. albicans, the level of ergosterol increased 
significantly without any detectable carboxysterol intermediates.  When expressing a non-fungal 
SQS, the level of ergosterol did not increase beyond that which was observed in yeast containing 
the empty vector.  This finding suggested that the yeast were unable to produce significant 
amounts of ergosterol.  Instead, GC analysis revealed two new lipid peaks.  These two peaks 
were also present following expression of a non-fungal SQS when the promoter was repressed 
and no exogenous ergosterol was present (SC glucose).  That suggested that the impaired 
growth observed in this media occurred by the same mechanism as growth inhibition following 
induction (Fig. 4.16).  Using the MS data obtained from these studies (Fig. 4.17) in comparison to 
a commercial vendor’s report for carboxy sterols [74], we tentatively identified the peaks as 
trimethylsilylated forms of a 4-methyl-4-carboxy-bisunsaturated sterol.  Since the parent ion 
(m/z = 586) was conserved between these two peaks, we suspected that these two compounds 
were epimers of one another. 
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Figure 4.15: Overexpression of a non-fungal SQS gene leads to accumulation of carboxy-sterol 
intermediates. Yeast line ZX178-08 (∆erg9) was transformed with an expression vector 
containing a galactose-inducible SQS gene from a yeast, S. cerevisiae or C. albicans; plant, A. 
thaliana (green); human, H. sapiens (yellow); or alga, B. braunii race B (blue). Cultures were 
grown in SCE glucose, centrifuged, and the cell pellets were resuspended in SCE galactose 
induction media.  After three days, cultures were density normalized; total lipids were extracted, 
derivatized, and analyzed by GC-MS.  In order to enhance visualization of the sterol metabolites, 
selective ion monitoring was used (m/z=468).  
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Figure 4.16: Low level expression of a non-fungal SQS led to accumulation of carboxy-sterol 
intermediates.  Yeast line ZX178-08 (∆erg9) was transformed with yeast S. cerevisiae (red) and 
algal B. braunii race B (blue) SQS genes under the control of a galactose-inducible promoter.  
Cultures were initially grown to stationary phase in non-inducing media with ergosterol (SCE 
glucose), centrifuged, and the cell pellets resuspended in the same media lacking a source of 
exogenous sterols (SC glucose).  Total lipids were extracted and derivatized for GC-MS analysis. 
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Figure 4.17: Mass spectra of putative carboxysterol intermediates.  The MS patterns for peaks 
with retention times 16.68 and 17.38 minutes in figure 4.16. 
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In order to further support our claim that the two peaks are carboxysterols, we profiled 
the sterol pathway of yeast grown in the presence of totarol, a compound isolated from the 
Podocarpus totara tree in New Zealand previously shown to inhibit the sterol C4-decarboxylase 
protein in yeast [75].  The wild-type yeast line BY4741 was incubated for three days with 150 
ng/mL of totarol which led to a 25% growth inhibition  Following total lipid extraction, 
derivatized sterols were examined by GC-MS.  Not only were the same two carboxysterol peaks 
present in the totarol treated yeast extracts, an additional peak with a mass spectrum consistent 
with a 4-carboxy-bisunsaturated sterol was observed (Fig. 4.18A-B).   
All together, these results suggest that while totarol only partially inhibits the sterol C4-
decarboxylase in yeast, lack of a fungal SQS C-terminal domain is far more disruptive to the 
demethylation step leading to almost complete growth inhibition.  It is also plausible that SQS is 
responsible for controlling the first decarboxylation step, but the second step is not inhibited, 
which would also account for the absence of 4-methylzymosterol in the total lipid extractions 
(Fig. 4.18C).  Regardless, additional studies such as NMR will be required to verify the identity of 
these two carboxysterol intermediates (as well as the position of the double bonds and 
stereochemistry of the 4-carboxy group) accumulating in the ∆erg9 yeast lines expressing non-
fungal SQS genes. 
As another method to confirm the role of these two putative carboxysterol peaks in 
yeast growth inhibition, we co-transformed the B. braunii race B SQS gene with a sterol C4-
decarboxylase gene (ERG26) from each kingdom of life or the mutant yeast SQS gene encoding 
for an inactive SQS enzyme.  Growth of the transformed lines was compared, as were the levels 
of the putative carboxysterols.  Each of these genes detoxified the yeast expressing a non-fungal 
SQS, returning a near or actual wild-type growth phenotype.  We therefore expected the 
resulting carboxysterol peaks from these combinations to be eliminated or at least greatly 
decreased in comparison to yeast expressing the non-fungal SQS alone.  While co-expression 
with the inactive yeast SQS or non-fungal ERG26 genes decreased the total carboxysterol level 
by more than 82%, co-expression of the algal SQS gene with the gene encoding the S. cerevisiae 
C4-decarboxylase only decreased the total carboxysterols by 27% (Fig. 4.19).  Yet, growth of this 
line was near normal under induction conditions (galactose).  It is conceivable that this was due 
to the carboxysterol accumulating during growth under the non-inducing conditions (SCE 
glucose), since the fungal C4-decarboxylase did not allow the non-fungal SQS to complement 
fully the ∆erg9 mutation when the promoter was repressed (Fig. 4.13). 
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Figure 4.18: Accumulation of three carboxysterol intermediates in wild-type yeast following 
totarol treatment.  Wild-type yeast line BY4741 was grown in complete media (YPD) with 150 
ng/mL totarol. Total lipids were extracted and derivatized for GC-MS analysis.  A) Peaks 1 and 2 
of the total lipid profile correspond to the previously identified carboxysterols.  B) The mass 
spectrum of the carboxysterol identified from peak 3.  C) A comparison of the function a fungal 
SQS may have in the C4 demethylation complex compared to totarol treatment.  The two 
enzymatic steps involving the sterol C4-decarboxylase (SDC) are numbered.
70 
Figure 4.19: Yeast expressing a non-fungal SQS have lower total carboxysterol levels when co-
expressing an inactive yeast SQS or a C4-decarboxylase.  Yeast line ZX178-08 (∆erg9) expressing 
an algal SQS from B. braunii race B (BbSQS) were co-transformed with an expression vector 
containing an inactive yeast SQS gene with an A183N mutation, an inactive algal SQS gene with 
an A177N mutation, or a sterol C4-decarboxylase gene (ERG26, SDC) from yeast (ScSDC), human 
(HsSDC), plant (AtSDC), or algal (BbSDC) cells.  Cultures were grown to mid-exponential phase 
and induced for three days.  Total lipids were extracted, derivatized, and analyzed by GC-MS 
using selective ion monitoring at m/z = 468. 
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Discussion 
It has been suggested that the C-terminal domain of SQS is responsible for either 
stabilizing the enzyme and preventing its degradation in vivo, or localizing it to the ER 
membrane [39].  While this domain contains the membrane spanning helix, we determined that 
fungal SQS proteins are required to prevent the accumulation of a toxic sterol.  This work 
furthers these findings by demonstrating that growth inhibition caused by expression of a non-
fungal SQS can be prevented by overexpressing a sterol C4-decarboxylase from any kingdom of 
life.  This led to a decrease in the accumulation of two carboxysterol intermediates.  These 
findings suggest that the mechanism for the C-terminal domain of SQS involves proper 
functioning of the yeast sterol C4-decarboxylase.  
Much like 3-ketosterols that destabilize the lipid bilayer and increase permeability of 
erythrocyte membranes, the accumulation of carboxysterols could be toxic due to changes in 
membrane fluidity and permeability [76].  In S. cerevisiae, accumulation of carboxysterol 
intermediates is accompanied by a dramatic decrease in growth as well as defects in the 
biosynthesis of membrane components including phosphatidic acid, phosphatidylinositol and 
mono-, di-, and triglycerides [67,73].  In animal cells, defects in the C4-decarboxylase protein 
(NSDHL) are associated with X-linked, male-lethal phenotypes in both mice and humans.  While 
mice develop phenotypes including bare patches (Bpa) and striated (Str), C4-decarboxylase 
mutations in humans lead to CHILD syndrome, a developmental disorder characterized by 
hemidysplasia, ichythyosiform erythroderma and limb defects [77,78].  Even plant growth is 
negatively affected by accumulating carboxysterol intermediates, which disrupt polar auxin 
transport and root development [79].  
While the C-terminal domain of SQS may not regulate stability or localization of SQS it 
may influence assembly of C4-decarboxylase into complexes affecting enzyme activity and 
protein stability.  Teske et al. observed that the sterol C3-ketoreductase in yeast also has a 
regulatory mechanism which is separate from its catalytic activity, and may be required for 
proper folding and conformation of the lanosterol synthase (Erg7) enzyme.  Even when the 
lanosterol synthase properly localized to the ER membrane, the ketoreductase was required for 
its activity, and the interaction between these two proteins was shown to be evolutionarily 
conserved among fungal sterol pathways.  Likewise, SQS may be required to chaperone the 
yeast C4-decarboxylase.  This could explain why the yeast C4-decarboxylase was unable to fully 
rescue growth of yeast expressing a non-fungal SQS without galactose induction.  The expressed 
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protein would have been too unstable, while the non-fungal C4-decarboxylase proteins would 
not necessarily be subject to the same regulation in yeast.   
While the yeast C4-decarboxylase does not contain a recognizable ER retrieval signal, 
studies have shown that this protein remains tethered to the ER membrane.  This is unlike many 
other proteins in the sterol pathway that localize both to the ER and either lipid particles or 
vesicles via recognizable membrane spanning motifs [80].  The C4-decarboxylase may, 
therefore, require another protein to act as a tether to the ER membrane.  Studies from the 
Bard laboratory have suggested that members of the C4 demethylation complex, either the 
sterol C4-methyloxidase (SMO, Erg25) protein or the Erg28 protein, may carry out this role as 
the former has a C-terminal ER retrieval signal and the latter acts as a scaffold protein for the 
complex [62,71].  While the Erg28 protein has been shown to interact with the C4-
methyloxidase, C4-decarboxylase, and C3-ketoreductase through yeast-2-hybrid analysis and co-
immunoprecipitation, it is possible that the yeast SQS may be more critical for regulating SDC 
localization in yeast [81,82].  Unlike in yeast, the plant, human, and algal C4-decarboxylase 
proteins all have C-terminal ER localization signals, which may also explain why these proteins 
are able to recover fully the growth of yeast expressing a non-fungal SQS even without galactose 
induction. 
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Chapter 5: Mapping a Kingdom-Specific Hinge Motif in the C-terminal 
Domain of Squalene Synthase 
Introduction 
Conventional drug design has focused primarily on inhibiting a protein, usually an 
enzyme or receptor, by targeting its active site or ligand-binding site.  In contrast, the inhibition 
of protein-protein interactions involved in many important cellular processes is an emerging 
area of drug design [83].  Protein-protein interactions are often categorized in two types: stable 
and transient.  Stable interactions are usually involved in creating macromolecular complexes 
such as the three enzymes that form RNA polymerase II, or likely the sterol C4 demethylation 
complex, and the interactions occur between domains [84].  Alternatively, transient interactions 
often mediate signaling and regulation processes.  These transient interactions generally occur 
between a short recognition motif, often a helix, which binds into a small groove in a relatively 
flat recognition domain [85].   
While developing drugs that target these interactions has proven challenging, there are 
some promising approaches [83].  Strategies include the production of large and complex drug 
molecules to fit the large interfaces between proteins or designing small molecules that bind 
weakly throughout the interface and then combining them to create a single lead with high 
affinity [86].  Perhaps the most successful method to date has been the development of small 
molecules and peptidomimetics that resemble the peptide motif involved in domain-motif 
interactions.  The interaction between p53 and its E3-ubiquitin ligase MDM2 has been one such 
targeted interaction with small molecule inhibitors currently in different phases of clinical trials 
[87].  These anticancer agents mimic a helix of p53 in order to target the binding cleft on MDM2.  
While peptides are limited in their ability to work as therapeutic agents by susceptibility 
to proteolysis and poor cell-penetrability, peptidomimetic agents involving non-canonical amino 
acids, stapling of helical conformations and cyclization are more promising [88,89].  For 
example, multiple laboratories are currently working on developing and testing compounds 
capable of mimicking the peptide motif of the protein second mitochondrial-derived activator of 
caspases (Smac) which binds to the BIR domains of carboxy-linked inhibitor of apoptosis protein 
(XIAP).  In so doing, they have been able to disrupt XIAP and release caspases to cause apoptosis 
of cancer cells [90,91]. 
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While it is not yet clear how SQS is involved in disrupting the fungal demethylation 
complex (see Chapter 4), it is quite likely that this phenotype involves a protein-protein 
interaction of some kind.  An analysis of the sterol biosynthetic complex using yeast 2-hybrid 
technology identified multiple binding partners for the yeast SQS, but only showed a weak 
interaction between SQS and the C4-decarboxylase [81].  This may mean that the interaction is 
transient or SQS has an effect on the C4-decarboxylase indirectly through other binding 
partners.  The aim of the work reported in this chapter was to identify the motif in the C-
terminal domain of S. cerevisiae SQS responsible for the growth inhibition phenotype and to test 
whether or not expression of the motif is able to disrupt an interaction and lead to yeast growth 
inhibition. 
Results 
Mapping a functional motif in the C-terminal domain of SQS 
To identify the structural feature(s) of SQS responsible for mediating the toxicity 
phenotype, we constructed chimeric genes and tested for their ability to complement the SQS 
knockout mutation.  Since Kribii et al. determined that the C-terminal 110 amino acids of the 
SQS from fission yeast S. pombe is enough for a plant SQS to complement the ∆erg9 mutation in 
yeast, we identified the corresponding region in the SQS genes from each kingdom of life and 
swapped these C-terminal domains in reciprocal fashion.  We transformed the yeast line ZX178-
08 with each chimeric gene, grew three independent transformants for each, serial diluted and 
spot plated the yeast on various media types (Fig. 5.1).  As expected, genes harboring the fungal 
C-terminal domain mimicked the phenotype of yeast expressing a full-length fungal SQS and 
grew in the tested conditions regardless of the source gene for the amino-terminal catalytic 
domain.  Those harboring any of the non-fungal C-terminal domains exhibited a limited ability to 
complement the ∆erg9 mutation when the promoter was repressed, and inhibited growth when 
induced. 
Since the complementation phenotype is specific to the fungal C-terminal domains, we 
aligned this region of multiple fungal SQS enzymes from S. cerevisiae, C. albicans, A. nidulans, 
and S. pombe and found only 8.3% identity between the sequences (Fig. 5.2).  While the 
membrane spanning helix showed very little conservation, a 26-amino acid sequence proximal  
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Figure 5.1: Mapping the SQS motif responsible for the functional complementation 
phenotype. Chimeric SQS genes were created by reciprocal exchanges of yeast, S. cerevisiae 
(red), and plant, A. thaliana (green) SQS genes. All gene constructs were inserted downstream of 
the galactose-inducible promoter, the resulting plasmids transformed into yeast line ZX178-08, 
and three independent transformants serial diluted five-fold onto inducing (galactose) and non-
inducing (glucose) media, with and without added ergosterol. 
76 
Figure 5.2: Alignments of the C-terminal domains of SQS enzymes from diverse fungi and from 
multiple kingdoms of life.   The C-terminal domains of SQS corresponding to the 110 C-terminal 
amino acids shown by Kribii et al. to be responsible for the kingdom-specific complementation 
of the ∆erg9 mutation in yeast were aligned using the clustal omega program.  (A) An alignment 
of fungal SQS C-terminal domains including S. cerevisiae, C. albicans, A. nidulans, and S. pombe.  
(B) An alignment of the C- terminal domains of SQS between kingdoms of life including a fungus, 
S. cerevisiae; plant, A. thaliana; animal, H. sapiens; and alga, B. braunii.  These C-terminal 
domains consist of a membrane spanning domain, preceded by a hinge domain that links the 
membrane spanning domain to the catalytic domain (not shown).  
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to the catalytic domain had a sequence identity of 38.5%.  We will subsequently refer to this 
sequence as the “hinge motif.”  The amino acid sequence of interest from the S. cerevisiae SQS 
is KSKLAVQDPNFLKLNIQISKIEQFME.  Of those 26 amino acids, two segments are the best 
conserved among fungal SQS proteins: DPNFLKL and KIEQ.  We then performed an alignment of 
the C-terminal domains of SQS across multiple kingdoms of life and found the previously 
identified hinge motif is not conserved between kingdoms other than the amino acids DPN, 
indicating that the motif may have a fungal-specific function.  According to a homology model of 
SQS, the “hinge motif” appears to reside adjacent to the catalytic domain and is composed of a 
short helical segment, followed by a loop and longer helix (Fig. 5.3).   
In order to evaluate this motif for its ability to convey the fungal-specific 
complementation phenotype to non-fungal SQS enzymes, we produced chimeric enzymes by 
reciprocally swapping only the hinge motif.  After transforming these constructs into ZX178-08 
and spot plating independent transformants, we discovered that each SQS, regardless of its 
kingdom of origin, was able to complement the knockout mutation when harboring a fungal 
hinge motif (Fig. 5.1).  The reverse was also true, in that each fungal SQS was incapable of fully 
complementing the ∆erg9 mutation when the sequence contained the 26 amino acids from a 
non-fungal SQS, and exhibited the toxicity phenotype.  GC-MS analysis of transformants 
harboring the chimeric SQS genes revealed accumulation of the two carboxysterol peaks, 
suggesting that the cause of toxicity for a fungal SQS with a non-fungal hinge and a full-length 
non-fungal enzyme was the same (Fig. 5.4). 
Further narrowing down the critical residues in the hinge motif 
Since small molecule therapeutics function best when mimicking a motif shorter than 
the full 26-amino acids, we next attempted to narrow this region of interest further.  We began 
by reciprocally swapping a segment of this sequence between the fungal S. cerevisiae SQS and 
the algal SQS from B. braunii race B.  Since the second helical segment displays the greatest 
conservation within the fungal kingdom, while the more N-terminal helix only shares a 
conserved lysine residue, we swapped only the C-terminal 16 amino acids: FLKLNIQISKIEQFME in 
the S. cerevisiae SQS and VTTTLEHLHKIKAACK in the B. braunii enzyme (Fig. 5.5).   
A fungal SQS with the 16 amino acids from the algal hinge motif was no longer able to 
complement the knockout mutation fully and was phenotypically similar to expression of a non-
fungal SQS, suggesting that the second helix was at least partially responsible for the  
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Figure 5.3: A homology model of S. cerevisiae SQS and the hinge motifs from each kingdom of 
life.  All homology models were generated using the crystal structure of the human SQS [92].  
The hinge motif of the native S. cerevisiae SQS (red) is indicated on the homology model (left).  
Hinge motifs from S. cerevisiae (red), A. thaliana (green), H. sapiens (yellow) and B. braunii 
(blue) SQS are depicted to the right.   
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Figure 5.4: Expression of SQS with a non-fungal hinge motif leads to carboxysterol 
accumulation.  Yeast line ZX178-08 (∆erg9) was transformed with two chimeric SQS genes: one 
from the alga B. braunii harboring a hinge motif from the yeast S. cerevisiae (red) and another 
from yeast with the algal hinge motif (blue). The cells were density normalized and total lipids 
were derivatized for GC-MS analysis with selective ion monitoring (m/z=468).  
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Figure 5.5: The SKIEQ amino acid sequence in the hinge motif is critical for the fungal SQS 
complementation phenotype.  Chimeric SQS genes were created by reciprocally swapping the 
nucleotide sequence responsible for the final 16 amino acids, producing an algal SQS from B. 
braunii (BbSQS) with the final 16 amino acids of the fungal S. cerevisiae hinge motif (red) and the 
fungal SQS (ScSQS) with the final 16 amino acids of the algal SQS (blue).  Chimeric yeast SQS 
genes were then produced by mutating nucleotide sequences within the second half of the 
hinge motif to the algal counterpart (blue). The chimeric genes were expressed in ZX178-08 
yeast (∆erg9). Independent transformants (rows) were grown initially in non-inducing media 
with added ergosterol (SCE glucose), diluted to a normalized density and five-fold serial dilutions 
were plated on media where the promoter is repressed (glucose) or induced (galactose) with or 
without ergosterol.  Images were taken after seven days of growth at 28 °C. 
81 
complementation phenotype.  However, the reciprocal was not as expected.  An algal SQS with 
the 16 amino acids from a fungal SQS did not complement the SQS knockout mutation in yeast, 
suggesting that the initial seven amino acids of the hinge motif are important for an interaction 
or for proper positioning of the second, well-conserved helix in vivo.  To further narrow down 
the critical 16 amino acids of the fungal SQS, we mutated regions within the second half of the S. 
cerevisiae SQS hinge motif to the algal counterpart.  Mutation of the first half of the 16 amino 
acid segment, FLKLNIQI, to the corresponding sequence in the algal hinge motif only marginally 
decreased the ability of the fungal SQS to complement the knockout mutation, while replacing 
the final fourth of the fungal hinge motif, SKIEQFME, with the corresponding sequence from the 
algal SQS led to the toxic growth phenotype.  Finally, the region of the fungal hinge motif most 
critical for the complementation phenotype was narrowed down to the SKIEQ amino acid 
sequence.  Previous work in our laboratory using a constitutive vector system mirrors the results 
shown here [32].   
Additional point mutations were produced in the S. cerevisiae SQS hinge motif to 
identify the contribution of post-translational modifications to the complementation phenotype. 
Since the C-terminal domain of S. cerevisiae SQS has been previously identified as a target for 
both ubiquitination and sumoylation [93–95], the lysine residues were mutated to arginine both 
singularly and in combinations (Fig. 5.6).  The serine residue was also mutated to cysteine to 
determine whether phosphorylation was required for complementation.  Spot plate analysis 
suggested that a post-translational modification at these residues was not responsible for the 
complementation phenotype.  Additional mutation of the lysine residues to glutamate showed 
that the positive charge at these positions was also not required for complementation.  
Mutating the serine residue alone did not result in any change in yeast growth. 
Expression of the fungal SQS hinge motif inhibits growth of wild-type yeast 
Since the yeast hinge motif is necessary for a SQS gene to complement the ∆erg9 yeast 
line and prevent toxicity, we speculated that this amino acid sequence is involved in an essential 
physical interaction with another protein.  Successful inhibitors of this sort of protein-protein 
interaction have been produced by mimicking the motif of one protein in order to compete for 
the binding partner.  So, we expressed the C-terminal domain of each SQS without the catalytic 
domain so see if they would out-compete the native yeast SQS for an interacting partner(s).  We 
cloned the C-terminal domains of SQS from various organisms into expression 
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Figure 5.6: Examination of specific residues in the fungal SQS hinge motif for their contribution 
to the complementation phenotype. Lysine to arginine or glutamate point mutations and a 
serine to cysteine mutation were introduced to the S. cerevisiae SQS gene and the resulting 
plasmids were transformed into yeast line ZX178-08 (∆erg9). Three independent transformants 
were serial dilution plated on to inducing (galactose) and non-inducing (glucose) media, with 
and without added ergosterol.  Yeast cultures were also grown in liquid SCE galactose media and 
the optical densities were recorded.  The amino acid sequence of the hinge motif highlighted for 
residues mutated is included for clarity.  
83 
vectors under the control of the pGAL10 promoter, creating constructs for  C-terminal domain 
expression, and using both the pGAL10 and pGAL1 divergent promoters for two-fold expression.  
Reciprocal chimeras of the hinge motif and membrane spanning helix were also produced, 
resulting plasmids were transformed into the wild-type yeast BY4741, and yeast growth was 
monitored using glucose (repression conditions) and galactose (induction conditions) liquid and 
solid media over time.  As wild-type yeast are not able to use exogenous sterols in aerobic 
conditions, no ergosterol was added to the growth media. 
As observed in the growth curve analysis (Fig. 5.7), none of the expressed C-terminal 
domains led to a decrease in the growth rate of the wild-type yeast in non-inducing media (SC 
glucose) compared to the empty vector control.  The doubling time for these cultures was 
approximately 3 hours.  Following galactose induction, constructs harboring two copies of a 
non-fungal C-terminal domain showed no adverse effects of growth relative to the vector 
control while yeast over-expressing two copies of a fungal SQS C-terminal domain were all 
dramatically growth impaired.  While the doubling time for yeast expressing a non-fungal C-
terminal domain under strong inducing conditions was approximately 10 hours, yeast expressing 
a fungal C-terminal domain had a doubling time of 30 hours.  By comparing one-fold and two-
fold expression of these domains (Fig. 5.8), it is clear that yeast growth inhibition was dose-
dependent.  Furthermore, expression of the chimeric C-terminal constructs with various hinge 
motifs and membrane spanning regions showed that the identity of the hinge region is indeed 
responsible for this decreased growth performance (Fig. 5.9).   
To verify that this growth inhibition occurs via the same mechanism as expression of a 
non-fungal SQS, we profiled the sterols by extracting non-saponifiable lipids or total lipids (Fig. 
5.10).  The wild-type yeast line BY4741 was transformed with expression vectors harboring two 
copies of either the S. cerevisiae SQS C-terminal domain or the non-fungal SQS C-terminal 
domains.  Yeast were grown in glucose without exogenous ergosterol to repress the promoter, 
and then induced for three days prior to extraction and analysis.  Yeast inhibited by the fungal C-
terminal domain displayed a very similar sterol profile when compared to yeast expressing non-
fungal C-terminal domains except for a slight increase in lanosterol and decrease in zymosterol 
accumulation.  The total lipid extraction did not reveal an increase in the level of carboxysterol 
intermediates.  As a final method to test the mechanism of growth inhibition, the yeast line 
ZX178-08 was transformed with the 1x and 2x C-terminal domain expression vectors and spot 
plated on glucose and galactose media with added ergosterol.  If growth inhibition was 
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Figure 5.7: Effects of fungal and non-fungal SQS carboxy-terminal (CT) domains on growth of 
wild-type BY4741 yeast.  Expression constructs harboring SQS carboxy-terminal domains 
comprising the hinge and membrane-spanning domains (without the corresponding amino-
terminal catalytic domains) were transformed into wild-type yeast and transformants grown in 
non-inducing (glucose) and inducing (galactose) media. As an additional control, the yeast SQS 
membrane-spanning helix (MH) was also tested.  Three independent transformants for each 
construct were grown to stationary phase in glucose media and used to inoculate liquid media 
containing either glucose or galactose. Growth was monitored as optical density measurements 
and the standard deviation was never greater than OD600=1. 
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Figure 5.8: Fungal SQS carboxy-terminal domain expression inhibits wild-type yeast in a dose 
dependent manner. Yeast line BY4741 was transformed with expression vectors harboring 
either one (1x) or two (2x) copies of a SQS carboxy-terminal domain (without the catalytic 
domain signified by an empty box) from the yeast, S. cerevisiae, C. albicans, and A. nidulans 
(red); plant, A. thaliana (green); human, H. sapiens (yellow); or alga, B. braunii (blue).  As a 
control, yeast were also transformed with constructs containing one or two copies of the S. 
cerevisiae membrane helix (MH) which does not include the hinge motif.  Three independent 
transformants representing each construct were initially grown in glucose media, and then 
serially diluted and spot plated onto media where the promoter was either repressed (glucose) 
or induced (galactose).   
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Figure 5.9: The fungal hinge motif is responsible for growth inhibition when expressing a SQS 
carboxy-terminal domain in wild-type yeast. Wild-type yeast line BY4741 was transformed with 
expression vectors harboring two copies of a chimeric SQS carboxy-terminal domain (without 
the catalytic domain signified by an empty box).  Each chimeric C-terminal domain included a 
hinge motif or membrane spanning helix from a yeast, S. cerevisiae (red); plant, A. thaliana 
(green); human, H. sapiens (yellow); or alga, B. braunii (blue). Three independent transformants 
representing each construct were grown in glucose media, serially diluted five-fold and spot 
plated.  Photographs were taken after 5 days of growth. 
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Figure 5.10: Profiling sterol accumulation following expression of a fungal C-terminal domain 
in wild-type yeast. Yeast line BY4741 was transformed with expression vectors harboring two 
(2x) copies of a SQS carboxy-terminal domain from a yeast, S. cerevisiae (red), or alga, B. braunii 
(blue).  Cultures were grown in glucose media, induced for 3 days prior to extraction of non-
saponifiable lipids.  Extracted lipids were derivatized prior to GC-MS analysis. 
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solely caused by accumulation of a downstream sterol intermediate, then expression of the 
fungal C-terminal domain would not be expected to inhibit yeast growth.  However, the same 
growth inhibition was seen in this yeast line as in the wild-type yeast BY4741 (Fig. 5.11).   
Discussion 
We have narrowed the region of the C-terminal domain responsible for modulating the 
toxicity phenotype associated with accumulation of the putative carboxysterol intermediates.  
This hinge motif appears to be serving some sort of structural role, perhaps helping to assemble 
the C4 demethylation complex in the downstream sterol pathway into an efficient, metabolic 
channel for ergosterol biosynthesis (Fig. 5.12).  Disruption of this metabolic channel, especially 
at the level of the sterol C4-decarboxylase, may also lead to impacts on sphingolipid and/or fatty 
acid metabolism in the ER membrane [67,73,96]. 
 This suggestion is corroborated by two additional observations.  First, over-expression 
of the hinge domain with a membrane spanning helix from any fungi, but not from a plant or 
animal SQS, resulted in a very significant reduction in the growth rate of wild type yeast.  Also, 
when we aligned the hinge domains from five fungal, five animal, five plant, and two algal SQS 
enzymes, a surprising degree of kingdom of life conservation and clustering is visible (Fig. 5.13).  
This has important implications.  If the hinge domains did not provide for some important 
physiological function as demonstrated for the fungal hinge domains, one would not expect 
such sequence conservation to have developed and been maintained.  Instead, if the hinge 
domains were only serving as linkers between the catalytic and membrane spanning domains, 
there would be much greater randomization much like the membrane spanning portion of these 
enzymes which retain hydrophobicity but not sequence identity within each kingdom.   
The fact that this region is not only fungal-specific, but appears to be kingdom-specific 
offers equally distinct opportunities for technological applications.  The fungal hinge domain 
does present itself as a target for antifungal therapeutic development, since our results 
demonstrate that interfering with the role of the hinge domain of SQS can lead to inhibition of 
fungal growth.  This was described earlier when we co-expressed the active fungal SQS with an 
inactive fungal SQS, and here where we greatly over-expressed the C-terminal domain of a 
fungal SQS in wild-type yeast.  Furthermore, we have demonstrated that only five amino acids of 
the fungal hinge motif need to be disrupted for yeast to manifest the toxic growth phenotype.   
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Figure 5.11: Fungal SQS carboxy-terminal domain expression inhibits yeast without a 
functional sterol biosynthetic pathway. Yeast line ZX178-08 (∆erg9 mutant) was transformed 
with expression vectors harboring either one (1x) or two (2x) copies of a SQS carboxy-terminal 
domain from fungi, S. cerevisiae, C. albicans, and A. nidulans (red); a plant, A. thaliana (green); a 
human, H. sapiens (yellow); or an alga, B. braunii (blue).  Three independent transformants were 
spot plated on media where the promoter was either repressed (glucose) or induced (galactose) 
with exogenous ergosterol.   
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Figure 5.12: A conceptual model for how the organization of the sterol pathway might be 
facilitated by a non-catalytic hinge motif of SQS. Ergosterol biosynthesis is associated with the 
cytoplasmic face of the endoplasmic reticulum, and the efficiency of the C4 demethylation 
complex may be facilitated by the organization of enzyme complexes.  The hinge motif of SQS 
would mediate the formation of these complexes, and expression of this enzyme with a hinge 
domain originating from a non-fungal SQS would not form such complexes, decreasing 
biosynthetic efficiency. 
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Figure 5.13: Comparison of the hinge motifs of squalene synthases across kingdoms of life. The 
hinge motif of S. cerevisiae (top line) was compared to the corresponding hinge motifs of four 
additional fungal SQS enzymes (red) as well as five plant (green), five animal (yellow) and two 
algal (blue) SQS enzymes. The structure above the alignment shows the predicted helix-loop-
helix structure of the sequence as depicted in the published crystal structure of the human 
enzyme.  Colored boxes show sequence identities for hinge motif amino acids within each 
kingdom, while gray shading illustrates conservation across all SQS enzymes. The percent 
sequence identity and similarity for each sequence compared to the S. cerevisiae hinge region is 
depicted to the right of the alignment beside a phylogenetic tree demonstrating the 
evolutionary relationship between these sequences.  
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This suggests that not only peptidomimetics but also small molecules could be used to 
affect a similar phenotypic outcome in pathogenic fungi.  Much like the development of MDM2 
inhibitors, which were modelled after a helical motif of the binding partner p53, the inhibitors 
could be modelled after the SKIEQ segment of the hinge motif and employed to inhibit the 
fungal C4-decarboxylase.  Recent advances in the study of the parasites responsible for causing 
Leishmaniasis and Chagas disease in humans also show that controlling ergosterol biosynthesis 
is a promising method for antiprotozoal therapy, and an alignment of the hinge domain of SQS 
from these organisms suggests that this motif can also be utilized as a target for therapeutic 
development (Fig. 5.14). The critical role that this domain has in the sterol biosynthetic pathway 
of all eukaryotes further presents opportunities for the development of unique reagents to 
modulate sterol metabolism in both animals and plants. 
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Figure 5.14: Alignment of hinge motifs from SQS enzymes in each kingdom of life including 
protozoans. (A) Alignment of the hinge motifs of SQS in each kingdom of life in comparison to 
the hinge motif of SQS from two protozoan parasites, Leishmania donovani and Trypanosoma 
cruzi. (B) A phylogenetic tree demonstrating the evolutionary relationship of the hinge motifs 
between multiple kingdoms of life including plants (green), fungi (red), vertebrates (yellow), 
algae (blue) and protozoans (purple). 
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Chapter 6: Additional Applications and Inferences: Investigating the 
Function of SQS Active Site Residues and Developing an Algorithm for 
Identifying Similar Motifs  
Introduction 
Not only do the findings in these studies present opportunities for the development of 
therapeutic agents, we also contend that the tools developed herein can be expanded to better 
understand the activity of SQS and related enzymes as well as a host of additional proteins 
conserved between kingdoms of life.   While we have focused on a non-catalytic region of 
squalene synthase, the phenotype associated with the hinge motif can be applied to studies 
involving the enzyme’s active site.  Advances in our understanding of the structure-function 
relationship of amino acid residues in SQS catalytic activity have the potential to improve 
production platforms for triterpenes used as vaccine adjuvants, pharmaceuticals, nutraceuticals, 
cosmetics, and biofuels [97,98].  Important studies performed with yeast and human SQS 
proteins, as well as the dehydrosqualene synthase from Staphylococcus aureus (CrtM), have 
provided insight into the mechanism of SQS catalytic activity, focusing primarily on the 
aspartate-rich motifs in the five helical domains that make up the active site pocket 
[27,37,40,99].  The crystallographic studies using human SQS have also identified likely regions 
involved in NADPH binding, however this has not been determined empirically and there are 
many more aspects of this and similar enzymes that have not been mapped [37].   
Initial studies in our laboratory interconverted residues from SQS in yeast with those in 
unique squalene synthase-like (SSL) enzymes found in algae to define which residues are 
involved in the first and second half reactions.  SSL enzymes from the algae B. braunii race B 
produce squalene and botryococcene [33]  These enzymes utilize the same two step mechanism 
of SQS, but do so in multiple enzymes.  SSL-1 catalyzes the first step, dimerizing the two 
molecules of FPP to produce PSPP.  This PSPP is released from the enzyme and becomes 
available for two additional enzymes.  SSL-2 uses PSPP and NADPH to produce 1’-1 linked 
squalene, while SSL-3 catalyzes a similar reaction but produces botryococcene with a 1’-3 
linkage.  This series of enzymes is distinct from the algal SQS which is also present in B. braunii 
and performs both the first and second half reactions for sterol biosynthesis [28].  The 
botryococcene oil associates with the extracellular matrix of the algae and is believed to provide 
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the buoyancy necessary to keep the algal colonies on the water’s surface where sunlight is 
readily available.   
 Using reciprocal mutations in the active sites of these SSL enzymes, Bell et al. discovered 
a double mutant (N171A, G207Q) in SSL-3 which converted its product specificity from 
botryococcene to squalene [100].  Interestingly, the opposite mutations in the algal SQS (A177N, 
Q213G) did not lead to botryococcene production.  These rational design approaches are made 
difficult by the low amino acid conservation between the SQS and SSL enzymes and would be 
improved by a screening platform able to select for squalene production from a pool of random 
mutant enzymes.  Since we have shown that a non-fungal SQS is capable of complementing a 
SQS knockout mutation in yeast when the pGAL10 promoter is not induced, we asked whether a 
combination of SSL-1 and SSL-2 could also complement the knockout mutation.  If so, then we 
supposed that SSL-3 mutants could be screened for their ability to produce squalene by 
selection on SC glucose media.  The work described below surrounding this effort was done in 
collaboration with Dr. Stephen Bell who was also a graduate student in the laboratory of Dr. Joe 
Chappell. 
 The findings related to the hinge motif of SQS also have broader implications for other 
conserved proteins involved in cell growth and metabolism.  We have presented evidence for 
the discovery of a protein motif associated with a highly conserved enzyme in eukaryotes that is 
distant from the catalytic site and yet is essential for genetic complementation.  We have 
further demonstrated that this motif is conserved within but not between kingdoms of life, that 
the hinge motif from plants and animals cannot replace the hinge motif of a fungal SQS.  We 
suggest that there are similar protein motifs associated with other enzymes that are kingdom of 
life specific and play essential physiological roles in eukaryotic cells.   
 Identifying these kingdom-specific motifs or domains in other proteins presents an 
interesting challenge.  Current protein databases search for protein sequences using functional 
domains such as active sites that are conserved not only within kingdoms of life, but between 
kingdoms as well.  Sequences such as the hinge motif that are conserved within but not 
between kingdoms show less conservation overall and are therefore overlooked.  Methods have 
been described that search for specialized functions in protein sub-families, such as ligand 
binding and protein-protein interactions, using protein sequence alignments.  Some of these 
methods, including SDPpred [101], ProustII [102], and Multi-harmony [103] allow the user to 
define the groups for analysis, and so can be used to look at proteins within kingdoms of life 
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rather than protein sub-families.  However, many of these methods have been shown to have 
modest and varying success identifying these sites.  In order to identify kingdom-specific motifs, 
we have designed a preliminary algorithm which compares amino acid conservation within 
verses across kingdoms of life and have validated the algorithm’s ability to identify the SQS 
hinge motif.  The work designing the algorithms to examine kingdom of life specific domains was 
done in collaboration with Dr. Jinze Liu’s laboratory in the Department of Computer Science, at 
the University of Kentucky and involved Corrine Elliott (undergraduate) and Satrio Husodo (post-
back student). 
Results 
Determining a complementation phenotype for SSL1-SSL3 constructs in ∆erg9 yeast 
In order to enhance our understanding of the active site residues necessary to produce 
squalene from FPP, we designed a library screening method to identify mutations able to 
convert the product specificity of SSL-3 from botryococcene to squalene.  Previous attempts to 
express the SSL-1 gene in a ∆erg9 yeast line led to growth inhibition, suggesting that the 
overproduction of PSPP or PSOH in yeast does lead to growth inhibition.  Co-expression of SSL-1 
and SSL-2 separately also led to growth inhibition, unlike expression of SSL-1 and the partially 
inactive yeast and algal SQS enzymes described in chapter 3.  This suggests that the substrate 
affinity of SSL-2 may not be high enough to efficiently convert PSPP into squalene.   
Given these findings, it is likely that attempts to mutate SSL-3 would also lead to poor 
substrate affinity.  Therefore, we used a version of SSL-1 linked to SSL-3 using a GGSGx3 linker 
sequence (SSL1-SSL3) [49].  Using the ZXB yeast line (∆erg9,1), we first expressed a variety of 
constructs harboring the SSL1-SSL3 linked gene, as well as a version with the N171A and G207Q 
mutations (SSL1-mtSSL3) already known to convert product specificity with and without the 
yeast C-terminal domain (YCT).  The C-terminal domain was added for two reasons.  We 
proposed first that adding a membrane spanning helix would help localize the enzyme and 
increase its access to the substrate FPP, and second that it would allow the squalene producing 
version of this dual enzyme to fully complement the SQS knockout mutation in yeast.  Cultures 
representing three colonies from each transformation were used to inoculate cultures which 
were grown at room temperature for 7 days to quantify the levels of botryococcene and 
squalene produced (Fig. 6.1A).   Expression of each of the SSL1-SSL3 genes in a yeast line that is 
not able to use squalene to produce sterols (ZXB) led to the identification of both botryococcene 
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Figure 6.1: The SSL1-mtSSL3YCT construct produces increased squalene in yeast which feeds 
into the sterol biosynthetic pathway. A) Expression vectors containing the SSL1-SSL3 gene with 
or without the mutations N171A and G207Q (mt) and with or without the C-terminal domain of 
S. cerevisiae SQS (YCT) were transformed into the ZXB yeast line (∆erg9,1).  Cultures were grown 
for 7 days at room temperature before they were extracted and triterpenes quantified by GC-
MS.  B) The same SSL1-SSL3 constructs were transformed into yeast line ZX178-08 (∆erg9), and 
cultures were induced for 3 days before ergosterol and carboxysterol intermediates were 
quantified.   
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and squalene by GC-MS, however the level of each product depended on which variation of this 
gene was expressed.  The SSL1-SSL3 protein without the two amino acid mutations in SSL-3 or 
the yeast C-terminal domain produced primarily botryococcene (7 µg/mL) with less than 2 
µg/mL of squalene.  Adding the two point mutations in the SSL-3 gene converted the product 
profile, leading to approximately 10 µg/mL of squalene and less than 2 µg/mL of botryococcene. 
The addition of the yeast SQS C-terminal domain clearly improved product accumulation, 
leading to 25 µg/mL botryococcene with the SSL1-SSL3YCT protein and almost 60 µg/mL of 
squalene when the SSL-3 gene was mutated.  This is not surprising since it has previously been 
demonstrated that expression of truncated forms of SQS led to very low product levels, 
suggesting that ER membrane localization is critical for efficient use of the substrate FPP [39].   
We then transformed each of the four constructs into the ZX178-08 yeast line (∆erg9) to 
analyze yeast growth when squalene was allowed to continue through the sterol biosynthetic 
pathway.  Colonies from each transformation were grown in SCE glucose and induced for 3 days 
in SCE galactose media prior to GC-MS analysis of the derivatized lipids (Fig. 6.1B).  Levels of 
both ergosterol and carboxysterols were assessed using a selective ion monitoring at m/z = 468. 
The levels of ergosterol stayed relatively steady independent of the gene being expressed, while 
the level of carboxysterols increased along with changes in squalene production.  Expression of 
the mutated SSL-3 genes led to the highest levels of carboxysterol intermediates, and the 
addition of the yeast C-terminal domain did not decrease accumulation of this toxic 
intermediate.  This suggests that while the hinge motif in the C-terminal domain of SQS is critical 
for preventing carboxysterol accumulation in the context of a full-length SQS, attaching the 
domain to another enzyme may disrupt the structure of the hinge motif, preventing it from 
assisting the C4 demethylation complex.   
While the addition of the yeast C-terminal domain to SSL1-SSL3 did not decrease the 
level of the toxic downstream intermediates, the presence of a membrane spanning helix did 
increase the overall production of both squalene and botryococcene. For this reason, we 
continued to use the genes containing this domain and proceeded to analyze yeast growth using 
spot plate analysis.  Three colonies from each transformation were grown in SCE glucose, 5x 
serial diluted and spotted on both glucose and galactose media with and without exogenous 
ergosterol (Fig. 6.2).  As expected, yeast expressing the SSL1-SSL3YCT, which primarily makes 
botryococcene, were only able to grow on media containing exogenous ergosterol, and growth 
was not inhibited by induced gene expression.  However, expressing the same gene with a  
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Figure 6.2: Expression of algal SQS genes produced by library mutagenesis and identified by 
screening for the non-fungal SQS growth phenotype. Expression constructs containing SSL1-
SSL3YCT (wild type) or mutated at potitions N171, M204, and G207 were transformed into yeast 
line ZX178-08 (∆erg9).  Transformants were grown in non-inducing media (SCE glucose) for five 
days before three independent transformants were spot plated onto non-inducing and inducing 
media with or without exogenous ergosterol. 
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mutated SSL-3 led to impaired growth on glucose media without exogenous ergosterol, and 
growth was fully inhibited once the promoter was induced by galactose, a phenotype identical 
to expression of a full-length non-fungal SQS.   
Library screening identifies mutations capable of converting the catalytic specificity of SSL3 
Since there was a clear difference in the growth phenotype of yeast expressing mutated 
and non-mutated SSL1-SSL3 enzymes, we next produced a library of mutations in SSL-3 involving 
amino acid positions 171 and 207.  If this selection platform was successful, we expected to 
uncover mutations capable of converting SSL1-SSL3YCT to a squalene synthase and to recover 
the known mutant gene SSL1-mtSSL3YCT with N171A and G207Q mutations.  Primers were 
designed for saturation mutagenesis, with the ability to produce a total of 400 possible mutants. 
In order to ensure that we were successfully mutating these positions to all possible amino 
acids, 47 random constructs from the library were purified from E. coli and sequenced.  We 
discovered that 75% were mutated at one or both of the targeted positions, and the frequency 
of substitution was 5-15% for each possible amino acid.  We then transformed the library into 
ZX178-08 yeast and selected for mutants on media that either repressed (SC glucose) or induced 
(SC galactose) the promoter without any exogenous ergosterol. 
Forty independent transformants were collected from the selection plates and the 
plasmids responsible for the partial complementation phenotype were isolated and sequenced. 
Two of the isolated constructs harbored SSL1-SSL3YCT genes without any mutations.  One of 
these was from an SC galactose plate (17gal8) and another from SC glucose (17glu13) while two 
were found to contain the expected mutations at amino acid positions 171 and 207 (17glu26 
and 17glu29).  These four constructs were transformed back into yeast line ZX178-08 and 
analyzed using spot plating on all four media types, SC glucose and SC galactose with and 
without exogenous ergosterol (Fig. 6.2).  Other mutations uncovered by this analysis are listed in 
Table 6.1.   
As expected, the constructs containing the chimeric gene without any additional SSL-3 
mutations were able to grow on media with exogenous ergosterol independent of the carbon 
source.  Interestingly, the two mutated constructs were able to grow on three of the four media 
types.  As expected, growth was robust on SCE glucose media, and greatly impaired on the same 
media without added ergosterol.  However, these transformed yeast were able to grow on 
galactose media with added ergosterol.  A closer look at the sequencing data from these  
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Table 6.1:  Independent clones recovered from the SSL1-SSL3YCT mutant library on SC glucose 
and SC galactose solid media.  ZX178-08 competent cells were transformed with the mutant 
library, and transformed yeast were allowed to recover in YPDE media for 18 hours and rinsed 
with sterile water prior to plating on both SC glucose and SC galactose solid plates.  Colonies 
grown within 15 days were isolated and the DNA sequenced. 
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constructs revealed an additional M204V mutation which could be contributing to this 
phenotype.   
Chemical profiling of these four enzymes showed that the two non-mutated constructs 
made botryococcene at expected levels, while 17glu26 and 17glu29 produced mostly squalene 
(Fig. 6.3).  17glu29 produced the same levels of squalene and botryococcene as SSL1-
mtSSL3YCT, which was surprising since yeast expressing this enzyme were able to grow on SCE 
galactose media.  This led us to suspect that the amount of squalene entering the sterol 
pathway was decreased.  On the other hand, the 17glu26 construct produced half the amount of 
squalene when compared to the SSL1-mtSSL3YCT control.  If this was due exclusively to the 
additional M204V mutation, then the same would have been true for 17glu29.  Therefore, there 
may be an additional mutation in the backbone of the expression vector of 17glu26 that changes 
the expression level of this enzyme and so decreases the amount of squalene accumulating.   
Developing a naïve algorithm able to highlight the hinge motif of squalene synthase 
The findings related to the hinge motif may have broader implications which extend 
beyond the sterol biosynthetic pathway.  The hinge motif uncovered when mapping the SQS 
complementation phenotype is highly conserved within each kingdom of life, but not between 
Kingdoms.  It is likely that this pattern can be identified in other proteins involved in cell growth 
and metabolism that are found in all eukaryotic cells.  Hence, we designed an algorithmic 
approach to identify these motifs on a broader scale, using SQS as an initial test case. 
We first used the existing T-Coffee program [104] to align five characterized SQS protein 
sequences from each kingdom of life: plant, animal, and fungal.  In order to identify kingdom-
specific regions of the alignment, each position was scored based on two conditions.  The first 
condition involved conservation within each individual kingdom of life (Ĉk).  For instance, if the 
second position in the alignment for the fungal SQS sequences is predominantly glycine, and it is 
present in four of five sequences, the fungal identity score for that position would be 0.8 (4/5).  
The second condition highly scored the positions in the alignment with amino acids that are 
highly conserved throughout all kingdoms of life (Ĉall), such as the initial methionine or those in 
the active site.  These positions would have a score of one (15/15).  The second position consists 
of nine glycine residues in 15 total sequences for a score of 0.6 (9/15).  These two values, within 
the fungal kingdom and between kingdoms, are then used to calculate fungal-specificity by 
subtracting the all-kingdom identity value from the fungal-specific identity value (0.8-0.6).  
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Figure 6.3: The 17glu26 and 17glu29 mutants have a converted product specificity but produce 
different levels of squalene. Expression vectors recovered from library mutagenesis containing 
the SSL1-SSL3YCT gene without (17gal8 and 17glu13) or with the mutations N171A, M204V, and 
G207Q (17glu26 and 17glu29) were transformed into the ZXB yeast line (∆erg9,1).  Starter 
cultures grown in SCE glucose were used to induce 3 mL of liquid SCE galactose media.  Cultures 
were grown for 7 days at room temperature before they were extracted and triterpenes 
quantified by GC-MS.   
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Kingdom-specificity (S) is then defined as the sum of the specificity values assigned to each 
individual kingdom (Ŝk) and the scores are normalized to a value between 0 and 1 (Fig. 6.4A).   
∏ −=∏=
k
allCkC
k
kSS
ˆˆˆ
The SQS hinge motif does not consist of a single or even a pair of highly conserved 
amino acids, but rather a series of 16 highly conserved and closely grouped amino acids folded 
into a 3-dimentional structure.  We therefore implemented a sliding window to highlight motifs 
rather than highly conserved but individual amino acids within the alignment (Fig. 6.4B).  The 
sliding window considers each position in the alignment and adjusts the score depending on the 
scores of the surrounding positions.  More specifically, the score at each position becomes the 
average of the score at that position and four positions in each direction.  This takes into 
account amino acids with R groups that would be in close proximity if the structure of the motif 
is an alpha helix with the expected 3.6 amino acids per turn.  The hinge motif then becomes the 
second highest scoring sequence within the fungal SQS protein.  Mapping the amino acid 
positions that have a kingdom-specificity score higher than 0.3 to the homology model of S. 
cerevisiae SQS highlights those motifs that are available for protein-protein interactions (Fig. 
6.4C).   
The results from this naïve algorithm were then compared to the available functionality 
predicting programs Proust II, SDPpred, and multi-harmony.  The Proust II server was only able 
to identify a single amino acid position near the amino-terminus of SQS with a Z score greater 
than 2.5.  Results from SDPpred and the two algorithms that are associated with multi-harmony 
are depicted in figure 6.5.  SDPpred results were converted into positive values for a more direct 
comparison to results from the other programs.  While each of these algorithms does identify 
the SQS hinge motif, it is not as clearly defined as the naïve algorithm. 
Discussion 
The active sites of squalene synthase and related triterpene synthases have been 
difficult to study in part due to the two step reaction mechanism.  The discovery of the squalene 
synthase-like enzymes in B. braunii provided a new method for exploring the requirements for 
each step independently.  Using these SSL enzymes, we sought to develop a screening method 
for investigating the effect of multiple amino acid mutations on squalene production.   
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Figure 6.4: The naïve algorithm for identifying kingdom-specific motifs identifies the hinge 
motif of SQS. (A) An alignment of 5 fungal, 5 plant, and 5 animal SQS proteins was analyzed 
using the naïve kingdom of life analysis (KoLa) algorithm and the resulting kingdom-specificity 
measures are graphed along the amino acid sequence from S. cerevisiae SQS. The hinge motif is 
shown in red.  (B) A sliding window was then implemented to add a weighted score to identify 
motifs with high kingdom-specificity. (C) An S. cerevisiae SQS homology model was colored 
according to the scores from the KoLa algorithm with a sliding window.  Amino acid positions 
with an adjusted score of 0.35 were colored red, while scores greater than 0.3 were colored 
purple. 
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Figure 6.5: Currently available algorithms do not clearly identify the SQS hinge motif.  The 
alignment of 5 fungal, 5 plant, and 5 animal SQS proteins was analyzed using the SDPpred and 
Multi-harmony (Sequence Harmony and Multi-relief) servers and the resulting functionality 
scores graphed for comparison to the naïve KoLa algorithm.  Amino acids corresponding to the 
hinge motif are colored red. 
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Our results show that the asparagine at positon 171 can be replaced by a less polar 
residue of similar size as long as the glycine at position 207 is mutated to a charged residue.  The 
difference between the production of botryococcene and squalene lies in the way the 
cyclopropyl intermediate PSPP is opened, leading to either a 1-1’ or 1-3’ linkage.  Since the two 
sites we chose for saturation mutagenesis, an asparagine at position 171 and glycine at position 
207, are involved in specifying one of these two products, they are likely responsible for 
determining how the cyclopropyl ring is oriented in the active site pocket.  Molecular modeling 
of these two enzymes based on the crystalized human SQS [100] shows that these residues may 
be located opposite each other with their R groups oriented into the active site.   
The presence of an additional M174V mutation in the two genes resembling SSL1-
mtSSL3YCT recovered from the library was unexpected.  Since the C-terminal domain of the 
yeast SQS did not allow the chimeric SSL gene to fully complement the SQS genetic deficiency in 
this yeast line, leading to carboxysterol accumulation, there was an additional pressure on this 
enzyme other than the need to produce squalene for ergosterol biosynthesis.  For instance, any 
mutations that would make the enzyme less stable, or more easily regulated, would be 
preferred as the amount of squalene entering the downstream pathway and accumulating as 
toxic intermediates could be more easily controlled.   
While the growth phenotype caused by expression of a SQS without a functioning fungal 
hinge motif has allowed us to begin investigating the role of active site residues in squalene 
biosynthesis, the knowledge gained from discovery of the hinge motif led to the development of 
a method for identifying additional kingdom-specific motifs.  What we have presented here is 
only an initial proof of principle, and many challenges remain before this approach is able to be 
used on a larger scale.  For instance, there must first be a method to identify proteins that are 
present and highly conserved in many kingdoms of life and collect grouped sequences that can 
be aligned.  The alignment algorithm that best supports the identification of kingdom-specific 
motifs must be determined, and even then dramatic changes in protein sequences within a 
kingdom of life have the potential to disrupt the overall alignment.  For this reason we plan on 
identifying a method to remove sequences that act as outliers in the alignment and score the 
alignments based on amino acid similarity as well as identity.  Once kingdom-specificity can be 
determined using a linear protein sequence, we must also consider protein three-dimensionality 
and the formation of kingdom-specific domains from protein folding.    
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Once developed, we believe that this algorithmic approach will shed light on 
evolutionary mechanisms regulating many critical cellular metabolic pathways and aid both in 
the generation of new therapeutics to control diseases and the biosynthesis of additional high-
value industrial products. 
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Chapter 7: Concluding Remarks 
This dissertation, explored the non-catalytic function of the C-terminal domain of SQS in 
the sterol biosynthetic pathway.  Beginning with a detailed description of the growth phenotype 
caused by expression of fungal and non-fungal SQS proteins in a ∆erg9 yeast line (Chapter 3), we 
discovered a likely cause of growth inhibition (Chapter 4) and mapped the motif in the C-
terminal domain of SQS responsible for the phenotype (Chapter 5) that will aide in the future 
development of a screening method for identifying novel antifungal agents.  Highlights of 
Chapter 3 include the observation that SQS genes from each kingdom of life were indeed able to 
complement a SQS genetic deficiency, although growth was impaired when the SQS was non-
fungal.  Overexpression of a SQS with catalytic activity but with a non-fungal C-terminal domain 
led to complete growth inhibition.  This was despite the finding that all SQS enzymes were 
expressed and active in yeast, and complementation or the lack thereof did not correlate with 
levels of squalene production in vivo.  This phenotype, though it occurred through a molecular 
mechanism distinct from SQS catalytic activity, was dependent on a functioning sterol pathway. 
In Chapter 4, this growth toxicity was mapped to the disruption of C4 demethylation, and more 
specifically a step involving sterol C4-decarboxylation (SDC), by manipulating carbon flux and 
profiling sterols within total lipid extractions. 
There are a number of directions in which this work could next be pursued.  Our work, 
as well as previous investigations with various SQS proteins, showed that this growth phenotype 
can be described as fungal versus non-fungal.  However, complementation of the SQS genetic 
deficiency has only been described for five fungal SQS proteins, and the lack of 
complementation with a limited number of non-fungal SQS proteins.  Further work would need 
to be completed with SQS genes from a much wider variety of organisms to be confident in the 
use of these terms.  The specific cause of growth inhibition caused by a missing fungal hinge 
motif also requires more investigation.  While we are here tentatively identifying the two peaks 
identified in yeast expressing a non-fungal SQS as carboxysterol epimers, these sterols must be 
purified and NMR studies performed to verify the identity of the accumulating sterols 
definitively.  Addition of the carboxysterol to yeast lines able to take up exogenous sterols 
would be expected to inhibit growth as well.  It is also unclear whether the SQS hinge motif 
interacts directly with the C4-decarboxylase or disrupts activity of the C4-decarboxylase through 
an indirect mechanism in the sterol biosynthetic complex.   
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The results in Chapter 5 return from the downstream sterol pathway to the C-terminal 
domain of SQS and identify the hinge motif responsible for mediating complementation of the 
SQS knockout mutation.  It is unclear why point mutations in this hinge motif do not seem to 
disrupt its ability to rescue C4-decarboxylase activity in yeast but can only confer the 
complementation phenotype to a non-fungal SQS if the entire motif is present.  Combinations of 
point mutations involving isosteric and isoelectronic substitutions will be required to explore the 
function of individual residues.  Perhaps most interesting, however, is the finding that this motif 
is not only fungal-specific, but may be kingdom specific as well.  We are not suggesting that this 
motif has the same function in each kingdom of life, but rather that it has a defined function in 
each kingdom which creates evolutionary pressure leading to sequence conservation over time. 
Additional experiments in plant and human cells are required to confirm that this claim is 
accurate.  Using the tools and findings in the previous chapters, we have begun the process of 
creating screening protocols and algorithms for characterizing the function of residues in the 
active site of SQS and identifying a variety of hinge-like kingdom-specific motifs. 
Many of the findings described throughout this dissertation lead us back to the 
development of a novel and promising antifungal agent based on the hinge motif of a fungal 
SQS.  There are a multitude of characteristics that must be considered when identifying a target 
that has potential for the production of an anti-infective agent.  For instance, it must be able to 
function against medically important pathogens.  While most of our work involved the growth of 
nonpathogenic brewer’s yeast, we have also confirmed that SQS proteins from the two most 
relevant genera of pathogenic fungi, Candida and Aspergillus, have hinge motifs that are capable 
of functioning in the same manner as the motif found in S. cerevisiae SQS.  It is also critical that 
any novel therapeutic has a mechanism that is broad spectrum among all similar infectious 
organisms without causing undue toxicity in the host.  The fungal-specificity, and perhaps even 
kingdom-specificity of the hinge motif identified here suggests that this would be the case for 
therapeutics designed according to this motif.  A newly developed anti-infective agent would 
also need to inhibit the growth of pathogens that have become resistant to existing drugs.  Since 
the most commonly administered antifungal agents, the azoles, function by the development of 
a side-pathway in ergosterol biosynthesis that includes the C4 demethylation complex, 
inhibition of a step in this complex would be beneficial.  An inhibitor that is designed to mimic 
the hinge motif of a fungal SQS and disrupt the downstream sterol C4-decarboxylase has the 
potential to be a safe and specific inhibitor of fungal growth.   
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APPENDIX A: Abbreviations 
BY4741 – Wild-type haploid yeast line 
C-terminal – Carboxy-terminal 
ER – Endoplasmic reticulum 
FPP – Farnesyl diphosphate 
GC-MS – Gas Chromatography-Mass Spectrometry 
NADPH – Nicotinamide adenine dinucleotide phosphate 
N-terminal – Amino-terminal 
PSOH – Presqualene alcohol 
PSPP – Presqualene diphosphate 
SC – Synthetic complete media 
SCE – Synthetic complete media with exogenous ergosterol 
SDC – Sterol C4-decarboxylase 
SKR – Sterol C3-ketoreductase 
SMO – Sterol C4-methyloxidase 
SSL-1 – Squalene synthase-like enzyme from B. braunii that converts FPP into PSPP 
SSL-2 – Squalene synthase-like enzyme from B. braunii that converts PSPP into squalene 
SSL-3 – Squalene synthase-like enzyme from B. braunii that converts PSPP into botryococcene 
SQS – Squalene synthase 
YCT – Yeast squalene synthase C-terminal domain 
ZX178-08 – Yeast line capable of exogenous sterol uptake with a ∆erg9 mutation 
ZXB – Yeast line capable of exogenous sterol uptake with ∆erg9 and ∆erg1 mutations 
ZXE – Yeast line capable of exogenous sterol uptake with ∆erg9 and ∆erg7 mutations 
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